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A B S T R A C T
background
Early detection of breast cancer (BC) with mammography may cause
overdiagnosis and overtreatment, detecting tumors which would re-
main undiagnosed for a lifetime, and impacting on quality of life.
The aims of this first area of study were: to model invasive BC in-
cidence trends in Catalonia (Spain) taking into account reproductive
and screening data; and to quantify the extent of BC overdiagnosis.
Quality of life is the most important outcome for advanced cancer
patients in palliative care. The aims of this second area of study were:
to perform a systematic review of all the clinical outcomes reported
in peer-reviewed publications after the supplementation with D3 or
ergocalciferol (D2); to assess serum vitamin D deficiency and its re-
lationship with quality of life, fatigue, and physical and functional
performance; and to design a randomized controlled trial to assess
cholecalciferol (D3) effectiveness in increasing quality of life.
methods
We modeled the incidence of invasive BC using a Poisson regression
model. Explanatory variables were age at diagnosis and cohort char-
acteristics (fertility rate, mammography use and year of birth). This
model was also used to estimate the background incidence in the
absence of screening. We used a probabilistic model to estimate the
expected BC incidence if women in the population used mammog-
raphy as reported in health surveys. The difference between the ob-
served and expected cumulative incidences provided an estimate of
overdiagnosis.
The systematic review included all the original research supple-
menting with D2 or D3 and reporting clinical outcomes. The search
strategy was run in MEDLINE and SCOPUS. The cross-sectional study
included 30 patients with the same inclusion/exclusion criteria as the
VIDAFACT study. It was designed, implemented and analyzed using
a bivariate analysis. We designed a randomised triple-blind phase
II/III placebo-controlled multicentre trial (VIDAFACT, with trial reg-
istration number: EudraCT: 2013-003478-29) to establish the evidence
for a beneficial effect of supplementing with 4,000 IU/day of D3 to
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advanced cancer patients in palliative care.
results
Incidence of invasive BC has increased among Catalan women, espe-
cially in birth cohorts from 1940 to 1955. These cohorts showed the
highest increase in BC incidence rates (more than doubled) for ages
50 to 65 years. Screening use of mammography was significantly as-
sociated with BC incidence and overdiagnosis. Our estimates of over-
diagnosis increased from 0.4% to 46.6%, for women born from 1935
to 1950.
The results of the systematic review contained no original research
reporting the results of randomized controlled trials of effectiveness
(phase III), and a very heterogeneous use of D3 and D2 in terms
of dosage and treatment duration. The results of the cross-sectional
study showed a significant association of fatigue and physical/func-
tional performance with serum vitamin D levels, although there was
no evidence of a direct association with quality of life. The first ran-
domized controlled trial to assess the effectiveness of D3 to improve
the quality of life of advanced cancer patients in palliative care has
been registered in the Spanish and European Medicines Agencies
(AEMPS and EMA) and approved by the hospital ethical committee.
The recruitment of patients will begin soon.
conclusions
Estimates support the existence of overdiagnosis in Catalonia attribu-
table to mammography usage. In view of the demonstrated risk of
overdiagnosis, women should be clearly informed. Future research in
BC screening should be oriented towards personalized screening and
risk assessment tools.
The results from both the cross-sectional study in advanced cancer
patients in palliative care and the systematic review on published out-
comes from studies reporting on supplementation with vitamin D2
or D3, support the need for VIDAFACT to provide data about vita-
min D supplementation effectiveness on improving overall quality of
life.
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R E S U M
context
La detecció precoç del càncer de mama (CM) mitjançant mamografia
pot causar sobrediagnòstic i sobretractament, és a dir, la detecció
de tumors que romandrien sense diagnosticar durant tota la vida,
disminuint la qualitat de vida. Els objectius d’aquesta primera àrea
d’estudi van ser: modelitzar les tendències d’incidència de CM inva-
sius a Catalunya (Espanya), tenint en compte dades sobre fecunditat
i cribratge; i quantificar el grau de sobrediagnòstic de CM.
La qualitat de vida és l’aspecte més important pels pacients amb
càncer avançat en cures pal·liatives. Els objectius d’aquesta segona
àrea d’estudi van ser els següents: dur a terme una revisió sistemàtica
de tots els resultats clínics publicats que tractin sobre els malalts de
càncer després de la suplementació amb D3 o ergocalciferol (D2);
avaluar la deficiència de vitamina D en sèrum i la seva relació amb la
qualitat de vida, la fatiga, i el rendiment físic i funcional; i dissenyar
un assaig controlat aleatori per avaluar l’eficàcia de colecalciferol (D3)
en l’augment de la qualitat de vida.
mètodes
La incidència de CM invasiu es va modelar utilitzant regressió de
Poisson. Les variables explicatives van ser l’edat al diagnòstic i les
característiques de la cohort (taxa de fertilitat, ús de la mamografia
i any de naixement). Aquest model també es va utilitzar per estimar
la incidència en absència de cribratge. Es va utilitzar un model pro-
babilístic per estimar la incidència de CM esperada si les dones en
la població utilitzen la mamografia com s’informa en les enquestes
de salut. La diferència entre les incidències acumulades observades i
esperades proporciona una estimació del sobrediagnòstic.
La revisió sistemàtica va incloure tots els estudis originals en que
els malalts van prendre D2 o D3 i van informar sobre els resultats
clínics. L’estratègia de cerca es va realitzar en MEDLINE i SCOPUS.
L’estudi transversal va incloure 30 pacients amb els mateixos criteris
d’inclusió / exclusió que l’estudi VIDAFACT. Va ser dissenyat, im-
plementat i analitzat utilitzant mètodes bivariants. Hem dissenyat un
assaig triple cec aleatoritzat fase II / III controlat amb placebo i mul-
ticèntric (VIDAFACT, amb número de registre de l’assaig: EudraCT:
ix
2013-003478-29) per establir l’evidència d’un efecte beneficiós de la
suplementació amb 4.000 UI / dia de D3 per als pacients amb càncer
avançat en cures pal·liatives.
resultats
La incidència de CM invasiu ha augmentat entre les dones catalanes,
especialment a les cohorts nascudes de 1940 a 1955. Aquestes cohorts
van mostrar el major augment en les taxes d’incidència de CM (més
del doble) per a les edats de 50 a 65 anys. L’ús de la mamografia
de cribratge es va associar significativament amb la incidència i so-
brediagnòstic de CM. Les nostres estimacions de sobrediagnòstic van
augmentar de 0,4 % al 46,6 %, per a les dones nascudes en 1935-1950.
Els resultats de la revisió sistemàtica no van detectar cap inves-
tigació original sobre els resultats dels assaigs controlats aleatoris
d’eficàcia (fase III), però sí un ús molt heterogeni de D3 i D2 en ter-
mes de dosi i durada del tractament. Els resultats de l’estudi transver-
sal van mostrar associació de la fatiga i el rendiment físic i funcional
amb els nivells de vitamina D en sèrum, encara que no es van ob-
servar evidències d’una associació directa amb la qualitat de vida. El
primer assaig controlat aleatori per avaluar l’eficàcia de D3 per mi-
llorar la qualitat de vida dels pacients amb càncer avançat en cures
pal·liatives ha estat registrat en les Agències de Medicaments espa-
nyoles i europees (AEMPS i EMA) i aprovat pel comité ètic de l’hos-
pital. En breu es començarà a reclutar pacients.
conclusions
Les nostres estimacions recolzen l’existència de sobrediagnòstic a Ca-
talunya atribuïble a l’ús de la mamografia. Atesa la presència de-
mostrada de risc de sobrediagnòstic, les dones han de rebre infor-
mació clara sobre aquest. La investigació futura en el cribratge de
CM s’ha d’orientar cap a eines d’avaluació de risc i detecció persona-
litzada.
Tant els resultats de l’estudi transversal en pacients amb càncer
avançat en cures pal·liatives com els resultats de la revisió sistemàtica
sobre els resultats publicats d’estudis que informen sobre la suple-
mentació amb vitamina D2 o D3 en pacients amb càncer, donen
suport a la necessitat de VIDAFACT per proporcionar dades sobre
l’eficàcia en termes de qualitat de vida general.
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R E S U M E N
contexto
La detección precoz del cáncer de mama (CM) mediante mamografía
puede causar sobrediagnóstico y sobretratamiento, es decir, la detec-
ción de tumores que permanecerían sin diagnosticar durante toda la
vida, disminuyendo la calidad de vida. Los objetivos de esta primera
área de estudio fueron: modelizar las tendencias de incidencia de CM
invasivos en Cataluña (España), teniendo en cuenta datos de fecun-
didad y cribado de las cohortes estudiadas; y cuantificar el grado de
sobrediagnóstico del CM.
La calidad de vida es el resultado más importante para los pa-
cientes con cáncer avanzado en cuidados paliativos. Los objetivos de
esta segunda área de estudio fueron los siguientes: llevar a cabo una
revisión sistemática de todos los resultados clínicos publicados so-
bre enfermos de cáncer tras la suplementación con colecalciferol D3
o ergoferol (D2); evaluar la deficiencia de vitamina D en suero y su
relación con la calidad de vida, la fatiga, y el rendimiento físico y
funcional; y diseñar un ensayo controlado aleatorio para evaluar la
eficacia de D3 en el aumento de la calidad de vida.
métodos
Modelizamos la incidencia de CM invasivo utilizando un modelo de
Poisson. Las variables explicativas fueron la edad al diagnóstico y las
características de la cohorte (tasa de fecundidad, uso de la mamo-
grafía y año de nacimiento). Este modelo también se utilizó para esti-
mar la incidencia basal en ausencia de cribado. Se utilizó un modelo
probabilístico para estimar la incidencia de CM esperado si las mu-
jeres en la población utilizaran la mamografía como se informa en las
encuestas de salud. La diferencia entre las incidencias acumuladas
observadas y esperadas proporciona una estimación del sobrediag-
nóstico.
La revisión sistemática incluyó todos los estudios originales que su-
plementaron con D2 o D3 e informaron sobre los resultados clínicos.
La estrategia de búsqueda se realizó en MEDLINE y SCOPUS. El es-
tudio transversal incluyó a 30 pacientes con los mismos criterios de
inclusión / exclusión que el estudio VIDAFACT. Fue diseñado, im-
plementado y analizado para aplicar un análisis bivariado. Hemos di-
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señado un ensayo multicéntrico triple ciego aleatorizado fase II / III
placebo-controlado (VIDAFACT, con número de registro: EudraCT:
2013-003478-29) para establecer la evidencia de un efecto beneficioso
de la suplementación con 4.000 UI / día de D3 para los pacientes con
cáncer avanzado en cuidados paliativos.
resultados
La incidencia de CM invasivo ha aumentado entre las mujeres cata-
lanas, especialmente en las cohortes nacidas de 1940 a 1955. Estas
cohortes mostraron el mayor aumento en las tasas de incidencia de
CM (más del doble) para las edades de 50 a 65 años. El uso de mamo-
grafía de cribado se asoció significativamente con la incidencia y so-
brediagnóstico de CM. Nuestras estimaciones de sobrediagnóstico au-
mentaron de 0,4 % al 46,6 %, para las mujeres nacidas en 1935-1950.
Los resultados de la revisión sistemática no mostraron ningún re-
sultado de ensayos aleatorios controlados de eficacia (fase III), y sí un
uso muy heterogéneo de D3 y D2 en términos de dosis y duración
del tratamiento. Los resultados del estudio transversal mostraron una
asociación significativa de la fatiga y el rendimiento físico y funcional
con los niveles de vitamina D en suero, aunque no se observó eviden-
cia de una asociación directa con la calidad de vida. El primer ensayo
controlado aleatorio para evaluar la eficacia de D3 para mejorar la
calidad de vida de los pacientes con cáncer avanzado en cuidados
paliativos ha sido registrado en las Agencias de Medicamentos es-
pañolas y europeas (AEMPS y EMA) y aprobado por el comité ético
del hospital. Se empezará a reclutar pacientes próximamente.
conclusiones
Nuestras estimaciones apoyan la existencia de sobrediagnóstico en
Cataluña atribuible al uso de la mamografía. Dada la presencia de-
mostrada de riesgo de sobrediagnóstico, las mujeres deben recibir in-
formación clara sobre éste. La investigación futura debe orientarse ha-
cia herramientas de evaluación de riesgo y detección personalizada.
Los resultados del estudio transversal en pacientes con cáncer avan-
zado y los resultados de la revisión sistemática de estudios publica-
dos que informan sobre la suplementación con vitamina D2 o D3 en
pacientes con cáncer, apoyan la necesidad de VIDAFACT para propor-
cionar datos sobre la eficacia en términos de calidad de vida general
con un ensayo clínico en pacientes con cáncer en cuidados paliativos.
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Today we fight.
Tomorrow we fight.
The day after, we fight.
And if this disease plans on whipping us, it better brings a lunch, ’cause it’s
gonna have a long day doing it.
—Beaver, 2008
You need to spend time crawling alone through shadows
to truly appreciate what it is to stand in the sun.
—Hick, 2014
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Part I
I N T R O D U C T I O N

1
B A C K G R O U N D
Much of the recent debate on the early detection of breast cancer
through mammography screening revolves around overdiagnosis, or
the diagnosis of a condition that would cause neither symptoms nor
death. Although screening tests can cause damage (such as pain and
anxiety from mammographies and biopsies), this is usually transient.
The consequences of cancer overdiagnosis and subsequent treatment
lasts a lifetime. The surgical treatment involves risks from anaesthe-
sia and surgical complications. Possible short-term side effects of ad-
juvant treatments include hair loss, neutropenic sepsis, hot flashes,
vaginal dryness, and increased risk of fracture for patients receiving
endocrine therapy. Possible long-term consequences include cardio-
vascular and respiratory complications if the patient receives radio-
therapy. One unavoidable consequence for an individual diagnosed
with cancer by a screening test is the decrease in quality of life, high-
lighting the need to quantify the amount of overdiagnosis associated
with early detection by screening mammography.
If it is important to preserve quality of life in healthy women at-
tending mammographic screening, then for patients with advanced
cancer in palliative care, quality of life is of the greatest importance.
Palliative care involves the prevention, improvement or the control
of symptoms like asthenia, caquexia, functional limitation and auton-
omy loss. Given the multiple health benefits associated with normal
vitamin D levels in healthy individuals, we decided to start a new
line of research on vitamin D supplementation in advanced cancer. It
includes a systematic review, a cross-sectional study and the design
of a randomized controlled trial with the aim of assessing the efficacy
of vitamin D3 supplementation (cholecalciferol) in advanced cancer
patients. Our objective is to provide scientific evidence of the effects
of a non-costly treatment for patients receiving palliative care on their
quality of life.
3
4 background
1.1 overdiagnosis of breast cancer
In Western countries, mortality from breast cancer (BC) has shown
a decreasing trend since 1990. In the US, the use of both screening
mammography and adjuvant treatments have had a similar role in
this reduction (Cronin 2006). Unfortunately, BC is still the most fre-
quent cancer in women and the leading cause of death in women
aged 35 to 64 (Ferlay 2004). In Spain, BC ranks third for malignant
neoplasia in disability-adjusted life years lost, after lung and colorec-
tal cancers.
One of the possible adverse effects of mammographic screening is
overdiagnosis or detection of lesions that, had they not been detected,
would have been silent throughout the woman’s lifetime. Along with
false positive and negative results, overdiagnosis is considered to be
an adverse effect of screening. For an individual, since most people
who are diagnosed are also treated, it is difficult to assess whether
overdiagnosis has occurred.
Most of the inferences about overdiagnosis come from population-
based studies. An evidence of overdiagnosis came from the long-term
follow-up of the Malmo randomized trial of mammography screen-
ing, in which there was an excess of 115 (10%) detected breast cancers
in the screened group 15 years after the trial was completed. Over-
diagnosis has also been identified in chest x-ray screening for lung
cancer. Long-term follow-up of the Mayo Clinic randomized trial of
screening with chest x-rays and sputum cytology found an excess of
46 lung cancer cases in the screened group 13 years after the trial
was completed, suggesting that 20-40% of lung cancers detected by
conventional x-ray screening represent overdiagnosis. Overdiagnosis
is also present in the high increase of new cases of prostate cancer
observed following the introduction of the prostate specific antigen
(PSA) screening test. Autopsies have also revealed a non-negligible
prevalence of indolent tumors in people who died from other causes.
Given all these evidences, a conference on preventing overdiagnosis
is organized every year since 2013 by the National institutes of Health
and the National Cancer Institute in the USA.
Screen-detected cancers have a higher probability of being slow-
growing cancers. Some of the screen-detected cancers will not cause
symptoms during a person’s life. Although the concept of non pro-
gressive cancers may not seem plausible, basic scientists have found
some biologic mechanisms that could explain the lack of progression.
Some cancers outgrow their blood supply and are starved, others are
recognized by the host’s immune system and are successfully con-
tained, and some are indolent tumors. In fact, the American Society
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of Medical Oncology (ASCO) has started a debate to change the name
of the ductal carcinoma in situ and the high-grade prostatic intraep-
ithelial neoplasia. These are premalignant conditions that should not
be labeled as cancers or neoplasia, nor should the word ‘cancer’ be
in the name. They propose to reclassify such conditions as indolent
lesions of epithelial origin (IDLE) (Esserman, 2013).
The estimates of overdiagnosis in breast cancer are highly variable
depending on the study design and methodology used. Thus, Paci
et al estimated it at 4.6% (Paci 2006), whereas Zahl et al estimated
that it affects a third part of the tumours detected in women aged
50 to 69 (Zahl 2008). A literature review in 2012 by Puliti et al esti-
mated overdiagnosis between 1 and 10% (Puliti 2012). The methodol-
ogy used to estimate overdiagnosis varies widely, as does their esti-
mated magnitude. Randomized controlled trials have low risk of bias
but limited generalizability. Ecological and cohort studies are limited
by data quality, follow-up length and the potential for population
level confounders. Pathological or imaging studies are based on ex-
amining overdiagnosis resulting from non-progressive disease and
not competing mortality and are limited by assuming that patholog-
ical or imaging characteristics were directly and strongly correlated
with cancer related morbidity and mortality. Finally, mathematical
models require complex mathematical equations simulating the natu-
ral (and unknown) course of screen detected cancer, obtaining results
in a shorter time.
When randomized clinical trials are difficult to undertake, mathe-
matical models that use all available data from either observational
studies or clinical trials or cancer registries may be a good alternative.
Mathematical models have been used by several research groups sup-
ported by the National Cancer Institute in the US and the Cancer
Intervention and Surveillance Modeling Network (CISNET) (CISNET
2008). One of these research groups was led by Sandra Lee and Mar-
vin Zelen who together developed a very detailed analytical model
(Lee 2008). We have used this model to estimate the expected num-
ber of breast cancer cases in the absence of overdiagnosis and also to
assess the excess of cases that can be attributed to the use of mam-
mography for the early detection of breast cancer in relation to the
observed breast cancer incidence.
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1.2 quality of life in advanced cancer
Palliative care is defined as the discipline whose aims are to minimize
symptoms, to relieve suffering and to work to achieve the best possi-
ble quality of life, when the disease cannot be cured. In this context,
to minimize the toxicity of any treatment is a priority.
Asthenia or cancer-related fatigue is the most frequent symptom in
patients treated by palliative care professionals, with a global preva-
lence of 90% in the early stages of the disease. Fatigue cannot be easily
diagnosed because it is usually masked by other symptoms such as
pain, nausea or shortness of breath. It will only be visible to patients
and physicians after the resolution of these problems. It is a symp-
tom that interferes largely on the autonomy of individuals, the basic
activities of daily life and has a huge impact on emotional status and
the social/family environment.
In addition to the difficulties in detecting fatigue as a symptom, the
assessment of its intensity is a challenge. Although there are tests that
measure the precise level of physical strength, fatigue is a symptom
with a very important emotional component related to the manage-
ment of losses. To adequately address these problems, specific ques-
tionnaires have been developed, which allow clinicians to measure
the perception of fatigue and its impact on quality of life (Stewart
2006 , Lane 2005).
Another open question is related to the choice of the most appropri-
ate treatment. Although the pathogenesis of cancer-related fatigue is
unclear, it is known that it is a multi-causal phenomenon. Physiologi-
cal and biochemical disorders have been identified which are directly
associated with tumor progression. In addition, there are serious ad-
verse effects resulting from the specific treatment of cancer; factors
related to physical and psychological stress; anemia, lack of exercise,
chronic pain, uncontrolled severe symptoms. All of them are often
present in most chronic diseases.
Among the multiple interventions studied, the ones that seem to of-
fer promising results and support a multimodal approach are: drug
therapy, exercise and nutritional interventions (Davis 2005). However,
for patients in palliative care, specific recommendations are scarce.
Exercise, framed within functional physiotherapy, must be custo-
mized and adapted to the limitations and potential of each person.
Its objective is not to achieve the highest level of activity, but to im-
prove and maintain physical resistance to keep muscle reserves.
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Several pharmacological interventions have been proposed includ-
ing erythropoietin to control anemia with controversial results; cor-
ticoids which convey a feeling of euphoria resulting in little or no
actual improvement of physical strength; progestagens which stimu-
late the appetite and increase weight (since fatigue is often associated
with malnourishment); hormonal interventions as megestrol-acetate
with non relevant benefits; psycho stimulants as methylphenidate ad-
ministered with some rapid success in both HIV and cancer patients
(Lower 2009, Martin 2001 Kerr 2012). However, these drugs elicit ad-
verse effects that impede their use in patients with high blood pres-
sure, brain tumors or arrhythmias.
The detection of symptoms of hypogonadism in patients with HIV
or cancer caused by their treatment, which result in fatigue and loss
of muscle mass, have been resolved with testosterone replacement
to correct low testosterone levels. Additional medication includes an
inhibitor of acetyl cholinesterase used to treat Alzheimer’s patients,
sympatheticmimetic agents and fluoro-cortisone, as well as L-carni-
tine, melanin-stimulant hormone, monoclonal antibodies against TNF
alpha, or COX 1 and COX2 inhibitors, each of which was directed to
one or a few components of the multifactorial pathogenesis of fatigue.
In view of the obvious urgent need to develop new evidence based
interventions for palliative care cancer patients, and based upon: 1)
the strong epidemiological relationship between vitamin D deficiency
and the high risk of mortality for all causes in the general population
(Adams 2010); 2) the high frequency of vitamin D deficiency in cancer
patients, and 3) the anti-cancer, anti-aging, anti-pain, immunomodu-
latory, and the protective renal, cardiovascular and neuro-muscular
properties of a normal vitamin D status (Adams 2010, Boullion 2008),
we propose that the simple, non-costly, and safe correction of vitamin
D deficiency in patients in palliative care could markedly improve
their quality of life. Indeed, in recent years, it has become appar-
ent that the health benefits of a normal vitamin D endocrine system
extend beyond the maintenance of normal calcium and phosphate
homeostasis and a healthy skeleton. In the general population, vi-
tamin D deficient individuals are at a higher risk of mortality for
all causes, including several disorders of aging such as cardiovascu-
lar disease, hypertension, diabetes, renal lesions, cancer, and autoim-
mune disease (Adams 2010, Boullion 2008).
Although the strongest epidemiological association does not con-
stitute a proof of causality, the clear delineation of the multiple mech-
anisms underlying vitamin D prosurvival actions support our hy-
pothesis. That is, that the implementation of inexpensive strategies to
correct vitamin D deficiency in patients in palliative care may prove
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cost-effective in preventing the onset and/or attenuating the progres-
sion of several of the multifactorial etiologies of cancer-related fatigue
caused by defective vitamin D control of: 1) cell growth causing hy-
perproliferative disorders, genomic instability, TACE-driven metas-
tasis, exacerbated growth and immune escape; and accelerated pro-
gression of cancer lesions (Adams 2010; Grotsky 2013; Dusso 2010;
2) DNA repair mechanisms causing age-associated disorders and re-
sistance to therapy in cancer (Gonzalez-Suarez 2011; Grostky 2013);
3) muscular weakness and impaired neuromuscular functions (Boul-
lion 2008, Napoli 2010); 4) musculoskeletal pain derived from cancer
treatment (Rastelli 2011); 5) the immune system causing increased
antigenicity in antigen presenting cells, reduced content of T regu-
latory lymphocytes, systemic inflammation and multiple organ dam-
age, as well as a higher propensity for autoimmune disorders (Adams
2010; Boullion 2008); 6) the integrity of the FGF23/klotho responsi-
ble for the anti-aging properties of klotho in the kidneys, in protect-
ing the vasculature from atheromatosis and calcification, and as a
tumor suppressor and protector from the onset of resistance in can-
cer treatment (Haussler 2012; Lim 2012, Wolf I 2008); 7) the renin-
angiotensin system to prevent hypertension, renal and cardiovascu-
lar damage due to excessive oxidative stress (Li 2010, Zhang 2011); 8)
acquisition of atherotrombotic phenotype of circulating monocytes-
macrophages and increased severity of atherosclerotic lesions (Oh
2009); 9) podocyte function to protect from proteinuria and proteinu-
ria-induced cardiovascular lesions (He 2011; DeBoer 2007).
Importantly, the multiple health disorders and the increased risk of
mortality associated with vitamin D deficiency are unrelated to abnor-
malities in serum levels of the vitamin D hormone, 1, 25−dihydroxy−
vitaminD (1,25D). Instead, the low serum 25 − hydroxyvitaminD
(25D) levels of vitamin D deficiency results in a lower local conver-
sion of 25D to 1,25D, causing defective autocrine/paracrine vitamin
D actions. For example, the simple correction of vitamin D deficiency
in African-Americans with an enhanced propensity to tuberculosis
outbursts, allows the local conversion of 25D to 1,25D in monocyte-
macrophages to induce the synthesis of cathelicidin to kill the my-
cobacterium.
Similar actions are expected to occur locally upon correction of vi-
tamin D defficiency in tumoral or metastatic cancer cells to suppress
further growth, or in multiple cell types attenuating inflammatory re-
sponses, enhancing muscular strength, reducing oxidative stress or
DNA damage, inducing anti-aging activities with minimal repercus-
sions in systemic calcium homeostasis, thereby reducing the risks of
potential vitamin D toxicity. The additive effects of these pleiotropic
vitamin D actions should safely improve the quality of life of patients
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in palliative care.
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T H I S T H E S I S
2.1 hypothesis
• Overdiagnosis of breast cancer in women attending breast can-
cer screening is not negligible and leads to overtreatment.
• The research with cholecalciferol or ergocalciferol in cancer is
scarce and suffers from the lack of randomized controlled trials
measuring efficacy.
• Perceived health-related quality of life, fatigue and physical per-
formance of patients with advanced cancer is associated with
25-hydroxyvitamin D serum levels.
• Patients with advanced cancer in palliative care could benefit
from supplementation with vitamin D.
2.2 objectives
1. To assess the magnitude of overdiagnosis attributable to mam-
mography screening for breast cancer.
2. To perform a systematic review of the published literature on
treatment with supplements of inactive vitamin D (D2 or D3)
in cancer patients.
3. To assess the association between serum levels of 25-hydroxy-
vitamin D and patient-perceived health-related quality of life,
fatigue and physical perfomance.
4. To design a randomized controlled trial to assess the efficacy of
a supplemental therapeutic modality with vitamin D3 designed
to improve the patient perceived health-related quality of life.
2.3 brief summary of the research articles of this the-
sis
The first article in Chapter 2 is titled Breast cancer incidence and over-
diagnosis in Catalonia (Spain). The aims of this study were to model
invasive breast cancer incidence trends taking into account reproduc-
tive and screening data, and to quantify the extent of breast cancer
overdiagnosis by screening mammography using mathematical mod-
els. It was published in Breast Cancer Research.
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The second article in Chapter 3 is titled Outcomes reported from sup-
plemention with vitamin D (cholecalciferol or ergocalciferol) to adult can-
cer patients. A systematic review. The aim of this review is to identify
and summarize all outcomes published in observational and experi-
mental clinical studies reporting the results obtained from the supple-
mentation of cancer patients with cholecalciferol or ergocalciferol. It
includes all adult patients with cancer at any stage. It has been sent
for consideration for publication to a peer-reviewed journal.
The third article in Chapter 4 is titled Vitamin D deficiency and its
association with fatigue and quality of life in advanced cancer patients un-
der palliative care. A cross-sectional study. The aim of this study was
to assess the relationship of Vitamin D deficiency with health-related
quality of life issues, fatigue and physical functioning in advanced
cancer patients. It is under peer-review in Palliative Medicine.
The fourth article in Chapter 5 is titled The effect on quality of life of vi-
tamin D administration for advanced cancer treatment (VIDAFACT study):
protocol of a randomised controlled trial. The primary aim of the proto-
col are to evaluate the efficacy of the administration of vitamin chole-
calciferol to enhance patient-reported HRQoL. The secondary aims
include: (1) To evaluate the efficacy of the administration of vitamin
D3 for enhancing physical performance, decreasing perceived fatigue
and achieving serum levels of 25(OH)D above 30 ng/mL; (2) To eval-
uate the effect on tumour biomarkers; (3) To explore the relationship
between vitamin D treatment compliance and 25(OH)D levels; (4) To
explore the relationship between 25(OH)D levels and renal function;
(5) To explore the dose–response relationship in the group of patients
with vitamin D3 for the main outcome; (6) and to assess the cost util-
ity of the proposed administration of vitamin D3. It was published in
BMJ Open.
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Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast
Cancer Research 2010, 12:R58
This published article estimates breast cancer incidence trends and,
particularly, the overdiagnosis attributable to the use of mamography
as an early detection screening tool to be applied in asymptomatic
women.
The overdiagnosis occurs when early detection finds a tumor that
would not have been diagnosed symptomatically. Among the factors
that could explain the overdiagnosis are the existence of competing
causes of death that act on the latency of tumors as well as a potential
fraction of tumors that remain encapsulated or even regress over time.
Our estimates are limited to invasive breast cancers and do not
include the ductal carcinoma in situ type, a pre-cancerous or non-
invasive cancerous lesion of the breast, classified as Stage 0, that
rarely produces symptoms or breast lumps and is usually detected
through screening mammography.
We used probability models based on the models developed by
Lee and Zelen (LZ) to estimate overdiagnosis. These models include
the density functions and the cumulative probability functions of the
phenomena involved in the incidence of breast cancer. These mod-
els take into account the lead time that results when breast cancer is
diagnosed earlier by using a screening tool. Lead time is defined as
the length of time between the early detection of an asymptomatic
tumor and its usual clinical (symptomatic) presentation. The popula-
tion included in the study are Spanish adult women 40 to 80 year old.
Different data sources, for cohorts born between 1930 and 1970, were
used.
To estimate the incidence of invasive breast cancer we used a Pois-
son regression model with explanatory variables age at diagnosis and
characteristics of the cohort, like completed fertility rate, percentage
of women using mammography at age 50, and year of birth. The year
of birth acts as a proxy of the remaining cohort characteristics for
which we do not have data over time, like use of hormone replace-
17
18 breast cancer incidence and overdiagnosis in catalonia (spain)
ment therapy, use of oral contraceptives, obesity, diet or health aware-
ness. This model was also used to estimate the baseline incidence
in the absence of screening. It applies a probabilistic model to esti-
mate the expected incidence of breast cancer based on the reported
mammography use in the Catalan health surveys. The difference be-
tween the observed and expected cumulative incidences provides an
estimate of overdiagnosis of invasive breast cancer associated to mam-
mography in Catalonia.
RESEARCH ARTICLE Open Access
Breast cancer incidence and overdiagnosis in
Catalonia (Spain)
Montserrat Martinez-Alonso1,2†, Ester Vilaprinyo3†, Rafael Marcos-Gragera4,5, Montserrat Rue1,2*
Abstract
Introduction: Early detection of breast cancer (BC) with mammography may cause overdiagnosis and
overtreatment, detecting tumors which would remain undiagnosed during a lifetime. The aims of this study were:
first, to model invasive BC incidence trends in Catalonia (Spain) taking into account reproductive and screening
data; and second, to quantify the extent of BC overdiagnosis.
Methods: We modeled the incidence of invasive BC using a Poisson regression model. Explanatory variables were:
age at diagnosis and cohort characteristics (completed fertility rate, percentage of women that use mammography
at age 50, and year of birth). This model also was used to estimate the background incidence in the absence of
screening. We used a probabilistic model to estimate the expected BC incidence if women in the population used
mammography as reported in health surveys. The difference between the observed and expected cumulative
incidences provided an estimate of overdiagnosis.
Results: Incidence of invasive BC increased, especially in cohorts born from 1940 to 1955. The biggest increase was
observed in these cohorts between the ages of 50 to 65 years, where the final BC incidence rates more than
doubled the initial ones. Dissemination of mammography was significantly associated with BC incidence and
overdiagnosis. Our estimates of overdiagnosis ranged from 0.4% to 46.6%, for women born around 1935 and 1950,
respectively.
Conclusions: Our results support the existence of overdiagnosis in Catalonia attributed to mammography usage,
and the limited malignant potential of some tumors may play an important role. Women should be better
informed about this risk. Research should be oriented towards personalized screening and risk assessment tools.
Introduction
Breast cancer (BC) incidence rates in women have been
increasing steadily in the 1980 s and 1990 s in many
countries. Time trends in the incidence of breast cancer
have been influenced by different factors: changes in
reproductive patterns, the introduction of screening
mammography, obesity trends, hormone replacement
therapy (HRT), oral contraceptive use and better health
awareness [1-10]. In Europe, BC incidence increased in
all countries, with or without national screening pro-
grams [6]. In Spain, where BC incidence is lower than
the European average, incidence rates have increased
since 1973, with a more marked rise during the 1990 s
[11] in parallel with the dissemination of mammogra-
phy, both opportunistic and publicly organized screen-
ing programs. In Catalonia (Spain), the annual
percentage change between 1980 to 1984 and 1995 to
1999 was 2.2% [12] and new cases of female BC were
estimated at 4,700 in the year 2008. This quantity repre-
sents 30% of all cancer diagnoses in women.
Screening increases incidence rates in three ways [13].
First, there is an immediate rise in incidence, due to the
early diagnosis of prevalent asymptomatic cancers
[14,15]. Second, age at diagnosis decreases as a result of
the lead time introduced by screening (estimated as two
to four years) [16]. Third, screening may cause overdiag-
nosis when it detects tumors which would never have
been diagnosed during a lifetime without screening
because of the lack of progressive potential or death
from other causes [17-21].
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Estimates of overdetection of invasive cancer may be
affected by important biases. Biesheuvel et al. mentioned
1) differences in the underlying breast cancer risk
between screened and unscreened populations, 2) con-
tamination of intervention and control groups, 3)
screening in the control group after the intervention
period ends, and 4) inadequate allowance for lead-time
[22]. It seems that the older trial data tend to provide
lower estimates of overdiagnosis, whereas the more
recent observational data tend toward higher estimates.
Since no decline in interval cancer rates has been
observed [23] part of the overdiagnosis increase may be
related to an increase in the sensitivity of mammogra-
phy (both for cancers that will progress and for tumors
of limited malignant potential).
Mathematical modeling may overcome some of the
previous mentioned biases. In the US, Holford estimated
the contribution of screening to the upward trend in BC
incidence using log-linear models for age, period and
birth cohort (APC) [24]. Holford’s models also provided
background estimates of trends that might have been
expected as a result of the continuation of historical
increases in the rates. The Cancer Intervention and Sur-
veillance Modeling Network (CISNET) used the back-
ground estimates as inputs for modeling the impact of
screening and adjuvant treatments on BC mortality
trends [25,26].
The interest in assessing the impact and cost-effective-
ness of breast cancer early detection programs in Cata-
lonia (Spain) led us to work with mathematical models
developed by Lee and Zelen within the CISNET [27,28].
The aims of this study are 1) to use reproductive and
screening data to model invasive BC incidence trends
and to obtain background estimates of invasive BC inci-
dence and 2) to use the Lee and Zelen mathematical
models to quantify the extent of overdetection of inva-
sive BC related to screening.
Materials and methods
Setting
In Spain there is a National Health System (NHS),
financed primarily by taxes, which provides universal
and free health coverage, including early detection of
breast cancer. Catalonia is an autonomous region of
Spain which has approximately one sixth of the Spanish
population. The Catalan Breast Cancer Screening Pro-
gram (BCSP) started gradually, at the beginning of the
1990 s, providing biennial mammography screening
tests to women 50 to 64 years old. Since the year 2000,
women older than 64 are kept in the program until the
age of 69. Before the start of and in addition to the
BCSP, there has also been a certain degree of opportu-
nistic breast cancer screening done in the public and
private health care sectors. In the 1994 Catalan Health
Survey, when most of the screening in Catalonia was
opportunistic, rates of screening mammography were
43% in women aged 40 to 49 years and 27% in women
aged 50 to 64 years [29]. In 2004, 61.2% of the invited
women participated in the BCSP and 75.7% either parti-
cipated in the BCSP or reported that they had received
recent mammograms (non-published BCSP data).
Data
To model invasive breast cancer incidence rates in Cata-
lonia, age and period specific incidence data were
obtained from the Girona and Tarragona population-
based cancer registries in Catalonia (both provinces
representing 18.5% of the total Catalan population and
covering either urban and rural areas). The Girona and
Tarragona provinces have around 750,000 and 800,000
inhabitants, respectively. Data from Girona was provided
directly by the Girona Cancer Registry and data from
Tarragona was downloaded from the International
Agency for Research on Cancer registries (IARC) [11].
Incidence data were available for calendar years 1980 to
1989 and 1991 to 2004 for Girona and 1983 to 1997 for
Tarragona. Given that the breast cancer incidence rates
in the Girona and Tarragona registries are similar [30],
both data sources were combined. Numerators for the
incidence rates were calculated adding the number of
incident cases from both registries by age and calendar
year. Denominators were calculated adding the number
of women at mid-calendar year, in the Girona and Tar-
ragona provinces, and were obtained from official census
population data [31]. We have assumed that the esti-
mated incidence rates were representative of the breast
cancer incidence in Catalonia. Ductal carcinoma in situ
(DCIS) has not been included in the analysis.
The research protocol was approved by the institu-
tional review board and ethics committee of the Hospi-
tal Universitari de Bellvitge (Barcelona) which waived
the need for informed consent.
Breast cancer incidence models
We modeled the observed incidence of invasive BC for
Catalan women aged 25 to 84 during the time period
1980 to 2004 using an age-cohort model that incorpo-
rated cohort characteristics like intensity of mammogra-
phy utilization and fecundity rate. We did not introduce
a period effect because screening mammography was
disseminated gradually in our country. We used this
model to estimate the background incidence of BC
under the assumption of no screening. Then, using a
probabilistic model that takes into account background
incidence, competing risks, distribution of sojourn time
in preclinical state, sensitivity of mammography and the
dissemination of screening in Catalonia, we estimated
the increased age-specific incidence due to lead time
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(expected incidence). Finally, we estimated overdiag-
nosis comparing the observed and expected cumulative
incidences, by cohort of birth. In the following sections
there are the models’ details.
Observed incidence model
Observed incidence rates were fitted using an age-
cohort model where the cohort effects were split into
three components. The first component refers to the
fecundity of the cohort and was measured using the
cohorts’ completed fertility rate (CFR). CFR is the aver-
age number of births per woman up to the end of the
childbearing years [32]. There is evidence that high par-
ity is protective of breast cancer independent of ages at
first and last full term pregnancies [33]. The second
component refers to the intensity that mammography
was used for each specific cohort and was measured as
the proportion of women who were having periodic
mammograms for early detection at age 50 (PM50).
This value was obtained from a previous work of model-
ing mammography dissemination in Catalonia (see the
details in Appendix A in Additional file 1) [34]. Finally,
the third component refers to the remaining cohort
characteristics once fecundity and mammography use
have been taken into account and for which we do not
have data over time, like use of HRT, use of oral contra-
ceptives, obesity, diet or health awareness. The third
component has been included in the model as the year
of birth of the cohorts.
Our BC incidence model uses age, CFR, PM50 and
year of birth to estimate the number of BC incident
cases by age and cohort of birth. It assumes a Poisson
distribution of the incident cases and takes into
account the exposed population. We used fractional
polynomials to describe the age and cohort effects in
order to increase the exibility of conventional polyno-
mial models and avoid undesirable artifacts of high-
order curves (see Appendix B in Additional file 1 and
reference [35] for more detail). Since mammography
use (PM50) and CFR had opposite trends in most of
the studied periods, and PM50 was strongly associated
with BC incidence, we decided to include CFR in the
model as an offset with the coefficient -0.15. This value
was obtained from the literature and indicates a rela-
tive risk of BC equal to 0.85 for each child born
[1,2,36].
Goodness of fit was assessed using the deviance and
the likelihood ratio test with respect to the saturated
model. Overdispersion of the Poisson model was
assessed. Plots of residuals versus fitted values and pre-
dictors were assessed to check for lack of fit related to
the scale of predictors (data not shown). Confidence
intervals of the predicted values were obtained using the
delta method and bootstrap.
Background incidence model
BC incidence in absence of screening, by cohort of birth,
was derived from the BC observed incidence model by
considering that the proportion of women having peri-
odic mammograms at age 50 (PM50) was zero. Confi-
dence intervals for background incidence were obtained
using the delta method and bootstrap.
Expected incidence and overdiagnosis estimation
Using the probabilistic model developed by Lee and
Zelen (LZ) for the CISNET [28] we estimated expected
BC incidence if women in the population had used
mammography as they reported in health surveys, and
overdiagnosis was zero. This estimate takes into account
the lead time that results when breast cancer is diag-
nosed earlier. Then the difference between the observed
and expected incidence provided an estimate of over-
diagnosis. The steps were the following (Figure 1):
1. We considered all the scenarios that assumed a)
100% of women starting screening mammography at age
z with 40 ≤ z ≤ wmax, where wmax is the highest age
attained by each cohort and b) the periodicity of the
exams was annual or biennial. For instance, for cohort
1950, wmax was 54, then z took 15 different values.
Therefore, for this cohort 30 different scenarios were
computed (15 with annual screening and 15 with bien-
nial screening).
2. We used the LZ model to estimate the number of
breast cancer incident cases by age and cohort of birth
in each of the scenarios mentioned in step 1, assuming
that each cohort had 100,000 women at birth. See the
equations in Appendices C and D in Additional file 1
and [28,37-40] for more detail.
3. We considered the dissemination of mammography
use in Catalonia by age and birth cohort in order to
obtain the scenario that best represents the real pattern
of mammography use for each cohort. Weighting the
estimates obtained for each scenario in step two by the
pattern of mammography use, we obtained the esti-
mated number of incident cases by age and birth cohort
(see Appendix B in Additional file 1).
4. For each cohort we obtained the expected cumula-
tive incidence (per 100,000 women at birth) adding the
incident cases obtained in step three. We represent this
estimate by CI e.
5. We estimated the observed cumulative incidence by
100,000 women at birth (CI o) multiplying the observed
age-specific incidence rates by the probability of being
alive at each age, and adding up all these values.
Finally the estimates of overdiagnosis by cohort of
birth were obtained using the formula:
100×
−CIo CIe
CIe
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Appendix E in Additional file 1 shows the calculation
of overdiagnosis for the cohort born in 1950 as an illus-
trative example.
The steps taken to obtain confidence intervals of the
overdiagnosis estimates are described in Appendix E.2
in Additional file 1.
Sensitivity of the overdiagnosis estimates to changes in
relevant parameters
We obtained new estimates of overdiagnosis by modify-
ing the following parameters:
1. Mean sojourn time in pre-clinical state (a). In the
LZ model a takes values in the range of two to four
years, depending on age. We estimated overdiagnosis
when a = 1 and when a = 5 for all ages. These scenar-
ios would represent tumors growing faster or slower
than in the LZ model, respectively.
2. Mammography sensitivity (b). In the LZ model b
varies from 0.35 to 0.8, depending on age of the woman
and year when mammography was performed. We esti-
mated the overdiagnosis assuming b = 0.9 for all ages.
3. Repeat mammography behavior. Since the distribu-
tions of periodicity of mammograms in Catalonia were
quite stable along different ages and calendar years, we
obtained new estimates of overdiagnosis in the most
extreme situations:
a. 1994 Health Survey for the age-group 40 to 49 years
(annual = 0.76, biennial = 0.21, irregular = 0.04).
b. 2006 Health Survey for ages from 60 to 69 years
(annual = 0.52, biennial = 0.35, irregular = 0.13).
Software
The Stata SE/10 statistical package was used to fit the
Poisson model for BC incidence, to bootstrap the resi-
duals and to obtain confidence intervals [41]. The Grid
Mathematica v6 program was used to apply the stochas-
tic LZ model, to estimate the number of BC incident
cases under different screening scenarios, and to esti-
mate overdiagnosis [42].
Results
Figure 2 shows the trend over time of the completed
fertility rate (CFR) (2a) and of the proportion of women
receiving periodic mammograms at age 50 (PM50) (2b),
two of the cohort variables used to model BC incidence.
Figure 1 Steps for estimating overdiagnosis for cohort 1950. See Appendix E.1 in Additional file 1 for a detailed description.
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Figure 2a shows that CFR decreased for women born
between 1900 and 1920 and then increased from 1920
to 1940, reaching a maximum of 2.35 children for
women born in 1940. After, the CFR decreased again.
Figure 2b shows a big increase in mammography usage
from 1935 to 1955. For a woman born after 1955 the
values of PM50 stabilized at approximately 0.8. It is
important to note that for women born between 1940
and 1955 we observed both a decrease of CFR and an
increase of PM50.
Table 1 shows the equation, the estimated coefficients
and standard errors of the BC incidence model. Frac-
tional polynomials selected powers two and three for
age, lineal for year of birth and power 0.5 for PM50.
Independent variables were centered with respect their
means. The model coefficients indicate that incidence
increased with age, year of birth and exposure to peri-
odic mammography. The square root effect of PM50 on
BC incidence indicates that the impact of mammogra-
phy use in BC incidence attenuated as PM50 increased.
The effect of fecundity on BC incidence was considered
inverse and constant overtime.
The observed BC incidence rates and the estimation
provided by the model can be observed in Figure 3
grouped by year of birth. There was agreement between
observed and predicted values. Data shows an increase
in BC incidence, especially in cohorts born from 1940 to
1955. The biggest increase of BC incidence was
observed for ages 50 to 65 years, where the lowest BC
incidence rate was less than half of the highest. The
slopes of the estimated rates for the oldest cohorts were
nearly parallel but we observed increasingly steeper
slopes for the 1935 and younger cohorts.
Figure 2 Completed fertility rate (CFR) and proportion having periodic mammograms at age 50 (PM50).
Table 1 Breast cancer incidence model; Catalonia 1980 to
2004
Coef. Std. error P-value
Age1 -38.8418 1.0854 < 0.001
Age2 0.0005 0.0002 0.002
PM501 0.6250 0.9878 < 0.001
YB1 0.0111 0.0026 < 0.001
Constant -6.0626 0.0156 < 0.001
The dependent variable is the number of observed incidence cases. The
model has an offset, which is a term with coefficient constrained to 1. offset =
log(exposed) 0.15 CFR, Age1 = (age/10)
-2 - 0.0331, Age2 = (age/10)
3 - 166.375,
PM501 = PM50
0.5 - 0.4342, YB1 = year-of-birth-1937.5. CFR: completed fertility
rate, PM50: proportion of women who were having periodic mammograms
for early detection at age 50. Deviance = 482.53. The expected number of
incident cases, E(I), can be obtained using the equation: E(I) = exp(-6.0626 -
38.8418 Age1 + 0.0005 Age2 + 0.6250PM501 + 0.0111YB1 + offset).
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Figure 4 shows the observed (dots), estimated (blue
dashed line) and background incidence rates for cohorts
1935, 1940, 1945 and 1950 (purple line). Confidence
intervals correspond to the bootstrap method and show
narrow estimations (intervals obtained by the delta
method were slightly narrower). Differences between
background and screening scenarios were insignificant
for woman born in 1935 or before (data not shown) and
increasingly higher for woman born later. This provided
the first clue to the magnitude of overdiagnosis due to
screening.
Figure 5 presents the number of incident BC cases
that would be obtained from a cohort of 100,000
women at birth in three different situations. The dashed
line indicates the number of cases under the background
incidence scenario and represents a situation of no
mammography use. The solid line indicates the number
of cases that would be diagnosed if mammography had
been used as reported in the Health Surveys. These esti-
mates were obtained by applying the LZ model to the
background incidence. The increase in incidence with
respect to the background is due to early diagnosis.
Dots represent the number of observed cases for
100,000 women at birth and have been obtained from
the observed incidence rates and probabilities of survi-
val. In the absence of overdiagnosis, the dots would
appear close to the solid line. The increasing distance
between the observed and expected values by cohort of
birth indicates that overdiagnosis has augmented over
time.
Table 2 shows the overdiagnosis estimates and confi-
dence intervals for cohorts born between 1935 and
1950. These estimates have been obtained by comparing
cumulative incidences from 40 years of age to the last
observed age in each cohort. Overdiagnosis estimates
vary from 0.4%, 95% CI (-8.8%, 12.2% ) for the 1935
cohort to 46.6%, 95% CI (22.7%, 85.2%) for the 1950
cohort.
Table 3 shows the results obtained after performing a
sensitivity analysis for the overdiagnosis estimates. The
largest change in overdiagnosis was observed when
modifying mean sojourn time in the pre-clinical state
(a). A pattern of mammography use caused a small
change in overdiagnosis (less than a 5% change between
the two extreme scenarios). Finally, the mammography
sensitivity caused changes of around 1.5% in the over-
diagnosis estimation.
Discussion
Principal findings
Breast cancer incidence in Catalonia has increased dur-
ing the twentieth century with a more marked rise in
cohorts born from 1940 to 1950, who were 30 to 40
years old at the beginning of the 1980 s. The progressive
dissemination of mammography in Catalonia was signifi-
cantly associated with this increase, once age and other
cohort characteristics were considered. Our estimates of
overdiagnosis ranged from 0.4% for women born in
1935 to 46.6% for women born in 1950.
Comparison with other studies
Incidence trends
Botha et al. studied breast cancer incidence and
mortality trends in 16 European countries until the
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Figure 3 Observed breast cancer (BC) incidence rates per 100,000 women (points) and the fitted model (lines). Each color represents a
cohort of birth.
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mid-1990 s. Increases in incidence occurred in all
countries, with or without national screening programs
and, according to the authors, were consistent with
changes in the risk factors [6]. In the USA, Holford et
al. also found an increased trend with a peak in the
mid-1980 s, when screening began to be more aggres-
sively promoted [24].
In Spain, Pollan et al. studied the trend over time of
the age-adjusted incidence rate of invasive breast cancer.
Incidence increased steadily during the 1980 s and 1990
s and it appeared to decline in 2000 to 2004 in the
Spanish provinces were screening had achieved full cov-
erage of the target population in a short time period
[43]. In Catalonia, where dissemination of screening
took longer, the change in the age adjusted incidence
trend was not observed.
In contrast to the previous studies, our incidence
model was not only designed to assess the trend of
breast cancer incidence over time but to obtain an esti-
mate of the background incidence and overdiagnosis.
Our results show a dramatic increase of age-specific
incidence rates in cohorts born after 1940 associated to
the intensity of mammography use in our region.
Overdiagnosis estimates
Overdiagnosis or overdetection estimates range from
negligible [15,44] or low [45-48] to moderate [22,49-51]
and high (50% or more) [14,52-55]. Some of the studies
did not account for lead time bias or for decreases in
incidence in older age groups no longer screened
[44,46].
A review of the eight randomized trials of mammogra-
phy found that in recent trials in which the control
group was not offered screening, an excess incidence of
breast cancer remained after many years of follow-up.
In those trials in which the control arm was offered
screening, there was no evidence of overdiagnosis,
although there was a possible shift from invasive to in
situ disease [56].
Two systematic reviews intended to shed light on
overdiagnosis of breast cancer. One of them, performed
by Biesheuvel et al. concluded that the most reliable
overdetection estimates ranged from -4% to 21% and
increased with age [22]. The other systematic review,
based on published trends in incidence of breast cancer
before and after the introduction of mammography
screening [53], included five national screening
Figure 4 Breast cancer (BC) incidence model for screening and background scenarios. Each plot shows the results for cohorts born in 1935,
1940, 1945 and 1950: observed BC incident rates per 100,000 women (points), model with (dashed blue line) and without (purple line) screening.
Confidence intervals were obtained using bootstrap.
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programs and estimated overdiagnosis in a 35% for inva-
sive cancers.
Two recent observational studies estimated overdiag-
nosis using population data. Puliti et al. [57] evaluated
the degree of overdiagnosis of breast cancer 15 years
after the introduction of service screening in Florence
(Italy). For women aged 60 to 69 years at the start of
the screening, the group that had a sufficient follow-up
period after the last screening, the authors did not find
overdiagnosis. In contrast, Morrell et al. [58], in New
South Walles (Australia) reported overdiagnosis esti-
mates of 30% and 42% (depending on the method used)
for women 50 to 69 years old. Although the study popu-
lations and methods used are different, our results are
consistent with both Puliti and Morrell studies. Similarly
to Puliti, we obtained no overdiagnosis for cohorts born
around 1935, which were in their 60 s when mammo-
graphy began to be widespread in Catalonia. And, con-
sistently to Morrell, we obtained estimates of
overdiagnosis higher than 40% for the younger cohorts
that had been intensively exposed to mammograms for
early detection.
Figure 5 Predicted breast cancer incidence rates per 100,000 women at birth. Each plot shows the results for cohorts born in 1935, 1940,
1945 and 1950: observed (points), background scenario (dashed gray line), and scenario that takes into account the actual dissemination of
mammography (purple line).
Table 2 Overdiagnosis estimation by year of birth in
Catalonia
Cohort Overdiagnosis (%) [95% conf. interval]
1935 0.4 -8.8 12.2
1940 23.3 9.1 43.4
1945 30.6 12.7 57.6
1950 46.6 22.7 85.2
Table 3 Sensitivity analysis for the cohort born in 1945
Screening pattern Parameter change Overdiagnosis (%)
Annual (z = 40) - 26.4
Annual (z = 40) b = 0.9 25.0
Annual (z = 40) a = 1 51.1
Annual (z = 40) a = 5 18.3
Biennial (z = 40) - 33.9
Mamo dissem 1994 for 40 to
49 years
- 33.8
Mamo dissem 2006 for 60 to
69 years
- 29.3
To test the sensitivity of the model we changed some of the parameters and
estimated overdiagnosis for woman born in 1945. The modified parameters
were mammography sensitivity (b) and mean sojourn time in pre-clinical state
(a). In the first five scenarios, 100% of the population started receiving
mammography at age 40 (z = 40). The last two scenarios take into account
the actual dissemination of mammography, and use as proportions of repeat
mammography behavior the most extreme vañues found in the different
health surveys (see Methods).
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Zahl et al., using a different approach, compared six-
year cumulative incidence of invasive breast cancer in a
screened and a control group in Norway [51]. All
women in the control group were invited to receive a 1-
time prevalence screen at the end of the observation
period. Since the cumulative incidence among controls
never reached that of the screened group (incidence rate
ratio = 1.22), the authors suggested that the natural
course of some screen-detected invasive breast cancers
may be to spontaneously regress. Similarly, Gotzsche et
al. in the update of the Cochrane systematic review of
screening for breast cancer with mammography esti-
mated that screening led to 30% overdiagnosis and over-
treatment, a figure consistent with our results [59].
Strengths and weaknesses
This study has several limitations: 1) Incidence data in
Catalonia was not available at the population level. The
two Catalan population based cancer registries, at the
Girona and Tarragona provinces, cover an area of
around 20% of the Catalan population. We have
assumed that the incidence of breast cancer from these
registries, was generalizable to the Catalan incidence.
We think that this assumption is acceptable because
even the cancer registries are geographically distant
within Catalonia, the incidence estimates were close.
Besides, both cancer registries report to the Interna-
tional Agency for Research on Cancer and comply with
its quality control procedures. 2) Incidence estimates
were available for a 25-year period, therefore some age-
specific incidence rates were not available. Although the
incidence model estimates were stable and precise, the
estimates of overdiagnosis for some cohorts had wide
confidence intervals. 3) We did not have information on
trends over time of important risk factors like HRT, oral
contraceptives, alcohol consumption obesity and seden-
tarism. We know that the use of HRT has been low in
Spain. During the 1990 s, the prevalence of HRT use
among Spanish women aged 45 to 64 increased progres-
sively reaching a value of 5.9% in 1998 and declined to
4.2% in 2006 [60,61]. Within a cohort of participants in
a population-based breast cancer screening program in
the city of Barcelona, the prevalence HRT peaked in
2002 at 11% in 50- to 54-year-olds and at 10.1% in 55-
to 59-year-olds, followed by a sudden reversal and a
progressive decrease [62]. Prevalence of overweight and
obesity in Spain has increased as in the majority of
other developed countries. A study of primary care
users in the Girona province showed that the proportion
of women with obesity (BMI < 30 kg/m2), in the 35 to
44 age group, increased from 6.9% in 1986 to 1989 to
12.9% in 1995 to 1999 [63]. The scarcity of information
on risk factors other than fecundity and mammography
use led us to include the year of birth in the model to
represent the remaining cohort effect. 4) Our breast
cancer incidence model used grouped data to estimate
the association between incidence rates and characteris-
tics of the exposed population at different periods of
time. Grouped data analysis may be affected by the eco-
logical fallacy or failure of aggregate level associations to
properly reflect individual level associations. We
intended to overcome this problem forcing the com-
pleted fertility rate variable to be inversely associated
with breast cancer incidence as reported in the litera-
ture. In addition, we included the effect of year of birth
in the incidence model as linear consistent with an
extended increasing trend over time. This assumption
provided a more conservative estimate of overdiagnosis
than when we fitted a higher degree polynomial func-
tion. 5) The estimates of mean sojourn time in a precli-
nical state that we have used are based on data from the
early detection randomized clinical trials [64] which did
not take overdiagnosis into account. That would have
caused mean sojourn time to appear longer than it was
[54]. If mean sojourn time in a preclinical state was
smaller than the values we used, our estimates of over-
diagnosis would be conservative (see Table 3 where our
sensitivity analysis shows the effect of changes in mean
sojourn time).
The principal strength of our study is the use of prob-
abilistic models to obtain the expected incidence of
breast cancer. Based on the background incidence and
the dissemination and patterns of use of mammography
in Catalonia we have estimated the increased age-speci-
fic incidence due to lead time. Our study does not com-
pare a screened group with a control group, it compares
the observed incidence rates with the expected ones
assuming that screening detects earlier invasive tumors
that would become apparent later during the womens’
life.
In comparison with the conventional age-period-
cohort (APC) models, our model includes two specific
cohort characteristics, the intensity of mammography
use and the completed fertility rate, which have opposite
trends during most of the study period. The agreement
between the observed and fitted incidence rates for
almost all the studied cohorts indicates the relevance of
this variables when explaining incidence changes over
time and the difficulties in interpreting APC models
when they include only one cohort effect that sum-
marizes divergent information.
Conclusions
Our results support the existence of overdiagnosis in
breast cancer screening by mammography in Catalonia.
Since our overdiagnosis estimates were high in cohorts
that have not reached the age of 60, where the impact
of competing risks is low, it seems that the limited
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malignant potential of some tumors may play an impor-
tant role in overdiagnosis. As other authors have recom-
mended [20,21], women should be informed about the
benefits and harms of screening and research should be
oriented towards assessing individual risk and incorpor-
ating it to optimize the effectiveness of screening.
Additional material
Additional file 1: Appendix. The file contains further details of the
model for dissemination of mammography, equations for the estimation
of BC incidence, prevalence, mortality, and overdiagnosis.
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APPENDIX
A Estimation of the proportion of women who were having periodic mammograms
for early detection at age 50
The following mixed effects model for dissemination of mammography in Catalonia was estimated in a
previous work [28]:
p =
φ1
1 + exp[(φ2 − age)/φ3] (1)
were p indicates the proportion of women receiving periodic mammograms, φ1 (asym) is the horizontal
asymptote as age increases or the proportion at which the curve levels off, φ2 (xmid) indicates the age
value at which approximately half of the population is receiving periodic mammograms and φ3 (scal)
indicates the difference in years between the age at which 3/4 of the population are receiving periodic
mammograms and the age φ2.
Dissemination curves were estimated for cohorts born in the calendar period 1938 to 1967. We could not
estimate dissemination curves for cohorts born before 1938 or after 1967 because data was scarce. The
parameters φ1 and φ3 were estimated as fixed effects and the parameter φ2 as random effect.
As shown in Table A1, for cohorts born in the calendar period 1938 to 1967, the proportions of women
having periodic mammograms at age 50 were estimated directly from the dissemination equation, setting
age = 50. For cohorts born before 1938, we used data from the Catalan Health Survey for year 1994 to
obtain the proportion of women having periodic mammograms by cohort of birth. For cohorts born after
1967 we used data from the Catalan Health Survey for year 2006. We used these proportions to estimate
the random parameter φ2 for each cohort and then we used the equation (1) to estimate the proportion of
women having mammograms at age 50.
1
Table A1.Number of women interviewed and percent reporting having periodical
mammograms. Catalan Health Surveys, calendar years 1994, 2002, and 2006.
Birth cohort Parameter φ2 PM50 Proportion of women
having periodic mammograms
1913-1917 96.92 0.0002 0.0335 a
1918-1922 88.99 0.0007 0.0563 a
1923-1927 80.24 0.0035 0.1067 a
1928-1932 70.93 0.0194 0.2094 a
1933-1937 64.69 0.0594 0.2497 a
1938-1942 56.78 0.2140 b
1943-1947 50.20 0.4750 b
1948-1952 44.76 0.7025 b
1953-1957 41.12 0.8120 b
1958-1962 39.84 0.8406 b
1963-1967 37.33 0.8840 b
1968-1972 41.61 0.7996 0.2523 c
1973-1977 39.08 0.8554 0.1764 c
aData obtained from the Catalan health survey 1994. bData estimated from the dissemination model. cData
obtained from the Catalan health survey 2006.
B Incidence models
Data for the observed incidence model was grouped in 5-year intervals, using the midpoint of the interval
as the representative value. Year of birth was estimated as the incidence period midpoint minus the age
midpoint. Since breast cancer incidence is very low before age 25 and it is affected by competing risks after
84 years of age, we modeled incidence data from 25 to 84 years of age.
Fractional polinomials were used to model the age and cohort effects on incidence. A fractional
polynomial of degree m with powers p = (p1, ..., pm) is defined as:
FP (m) = β1X
p1 + β2X
p2 + ...+ βmX
pm
Powers p are taken from a predefined set, for example {−2,−1,−0.5, 0, 0.5, 1, 2, 3} and power 0 means
log(X).
Mammography dissemination was incorporated in the model in the following way. A screening scenario
is characterized by a) the proportion of women that receive periodic mammographies at each age and by b)
the distribution of the exams’ periodicity (annual, biennial and higher periodicity or irregular). We used
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proportions from the Catalan survey from 2002 for ages in the 50-59 year interval (annual = 0.61, biennial
= 0.33, and irregular = 0.06). The proportion of irregular screening was split into two parts and each one
of them was added to the proportions of biennial and non-mammography.
The difference between the proportion of women that use periodic mammography at ages z + 1 and z is an
estimate of the proportion of women that started mammography at age z. We assumed that all women
that reported having mammograms at age 40 (initial age) had not received mammograms before.
Weighting the estimates obtained for each screening scenario by the pattern of mammography use, we
obtained the estimated number of incident cases by age and birth cohort.
C Estimation of the probability of surviving free of BC: Sν(t)
The probability of surviving free of disease, by cohort of birth ν, is one of the inputs of the mathematical
model. Sν(t) depends on mortality from causes other than breast cancer (competing risks [37-38]) and BC
incidence. To estimate Sν(t) we performed the following steps:
1. Obtain the central mortality rate at age u from other causes than breast cancer
m−bc(u) = mτ (u)−mbc(u) (2)
The all-cause and BC central death rates are labeled as mτ and mbc, respectively. The numerators of
the central rates are the number of deaths in the age interval. The denominators have been
approximated by the number in the population midway through the interval:
2. Assume that the instantaneous force of mortality λ−bcm is constant over the age interval [u, u+ 1) and
can be approximated by m−bc(u).
3. Obtain the incidence central rate i(u) and assume that it can approximate the instantaneous
incidence rate λi. Breast cancer incidence was estimated according to the incidence model in Table 1.
4. Obtain the hazard of failure either due to being a BC case or dying from other causes (λF ). We
assume that the two hazards are independent.
λF = λ−bcm + λi (3)
5. Solve the differential equation:
S′ν(t) = λ
FSν(t); Sν(0) = 1 (4)
3
D Equations for estimating breast cancer incidence probabilities
D.1 Background scenario
This section refers to the background scenario where BC is diagnosed only by routine care with no
screening. Data obtained under the background scenario will be compared to data obtained under the
screening scenario, therefore some of the notation is common for both situations and follows the work of
Lee and Zelen [28].
The age at which the study starts is denoted by z. In the screening scenario z is the age at which the first
screening exam is performed and t0 = 0 the time at which the first screening exam is performed or origin
time.
There are three chronological times (relative to t0 = 0) that must be taken into account in the formulas.
These are: x= the time at which the preclinical state, Sp, is entered, (x can be positive or negative), τ=
the time at which the clinical state is entered, and y= the time at death. The corresponding ages are z+ x,
z + τ and z + y and the sojourn times in Sp and Sc are (τ − x) and (y − τ), respectively.
We present the formulas used to estimate BC incidence for a specific cohort ν. Incidence probabilities and
mammography sensitivity vary by age and cohort of birth. For simplicity, the index ν that indicates birth
cohort is not shown in the notation.
The probability of being incident at the time interval [t, t+ 1) can be estimated using the formula:
I(t) =
∫ t+1
t
Sν(u)i(u)du (5)
where i(u) is the age and cohort specific incidence at time u.
D.2 Relationship between BC incidence and transition to the pre-clinical and clinical states Sp and Sc
Under screening we do not observe the time at which a BC will become symptomatic. Therefore, the
incidence distribution can not be used in the calculations. Instead, the Lee and Zelen models use the
transition probability S0 → Sp denoted by w(t)dt and the probability density function of the sojourn time
in the preclinical state, q(t) [40].
The following equation shows the equivalence between the estimation of incidence at age z + k, k = 0, 1, 2...
using the incidence i(t) or the w(t) and q(t) functions.
I(z + k) =
∫ k+1
k
Sν(z + τ)i(z + τ)dτ ≈
∫ k+1
k
∫ z
0
Sν(τ − x)w(τ − x)q(x)dxdτ (6)
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Also, the left side of this equivalence was used for the final estimation of background BC diagnosis.
D.3 Screening scenarios
This section presents the formulas used to perform the estimations under a generic screening scenario. A
pattern of screening is characterized by age interval and periodicity of exams. Survival distribution
functions and stage at diagnosis distribution are pattern specific.
Under a screening scenario, Lee and Zelen distinguish whether BC was detected in a screening exam or if it
was diagnosed in the interval between two screening exams.
D.3.1 BC detected at exam r
Lee and Zelen considered n examinations given at chronological times t0 < t1 < ... < tn−1. The first exam
is performed at age z and time t0 = 0. Each successive exam r is performed at time tr−1. For instance:
Exam number (r) 1 2 3 . . . r . . . n
Exam time for annual screening, in years (tr−1) 0 1 2 . . . r − 1 . . . n-1
Exam time for biennial screening, in years (tr−1) 0 2 4 . . . 2(r − 1) . . . 2(n-1)
The probability of detecting a BC in the first exam (t0) is
Det(t0, z) = β(z)
∫ z
0
Sν(z − x)w(z − x)Q(x)dx (7)
where
Q(t) =
∫ ∞
t
q(x)dx (8)
is the tail probability of the sojourn time in the preclinical state.
The probability of detecting a BC at time tr, Det(tr, z) takes into account if the transition to Sp was done
before (Detpre(tr, z)) or after (Detpost(tr, z)) the age z.
Det(tr, z) = Detpre(tr, z) +Detpost(tr, z) (9)
Detpre(tr, z) = β(z + tr)
(
r−1∏
i=0
(1− β(z + ti)
)∫ z
0
Sν(z − x)w(z − x)Q(tr + x)dx (10)
Detpost(tr, z) = β(z + tr)
r∑
j=1
i<r∏
i=j
(1− β(z + ti))
∫ tj
tj−1
Sν(z + x)w(z + x)Q(tr − x)dx (11)
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D.3.2 BC diagnosed in the interval (tr−1, tr)
Women diagnosed in the interval (tr−1, tr) may have entered the preclinical state Sp:
• before age z
• in the interval (tr−1, tr)
• in the interval (z, tr−1)
The probability of being diagnosed in the interval equals to the sum of these three probabilities. We
introduced an additional index, s, that allowed to obtain the estimates yearly when the screening scenario
has biennial periodicity or higher . Thus, s = 0 refers to the first year of the interval and s = 1 to the
second year and so on, successively.
Transition to preclinical state before age z:
Intpre(r, z, s) =
(
r−1∏
i=0
(1− β(z + ti))
)∫ tr−1+s+1
tr−1+s
∫ z
0
Sν(z − x)w(z − x)q(τ + x)dxdτ (12)
Transition to preclinical stage in the interval (tr−1, tr):
Intpost1(r, z, s) =
∫ tr−1+s+1
tr−1+s
∫ τ
tr−1
Sν(z + x)w(z + x)q(τ − x)dxdτ (13)
Transition to preclinical state in the interval (z, tr−1):
Intpost2(r, z, s) =
r∑
j=1
i<r∏
i=j
(1− β(z + ti))
∫ tr−1+s+1
tr−1+s
∫ tj
tj−1
Sν(z + x)w(z + x)q(τ − x)dxdτ (14)
D.3.3 BC diagnosed in an interval after the last exam, (tn−1 + s, tn−1 + s+ 1), s = 1, 2, ...
As in previous sections, the probability equals to the sum of the following:
Transition to the preclinical state before age z:
Intpre(n, z, s) =
(
n−1∏
i=0
(1− β(z + ti)
)∫ tn−1+s+1
tn−1+s
∫ z
0
Sν(z − x)w(z − x)q(τ + x)dxdτ (15)
Transition to the preclinical state in the interval (tn−1, tn−1 + s+ 1):
Intpost1(n, z, s) =
∫ tn−1+s+1
tn−1+s
∫ τ
tn−1
Sν(z + x)w(z + x)q(τ − x)dxdτ (16)
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Transition to the preclinical state in the interval (z, tn−1):
Intpost2(n, z, s) =
n∑
j=1
i<r∏
i=j
(1− β(z + ti))
∫ tn−1+s+1
tn−1+s
∫ tj
tj−1
Sν(z + x)w(z + x)q(τ − x)dxdτ (17)
D.3.4 Probability of being diagnosed
The probability of being diagnosed during a specific calendar year is the sum of the probability of being
detected at the exam (if it was performed) and the probability of being diagnosed in the interval between
two exams or after the last exam.
E Overdiagnosis
E.1 Example
Figure 1 illustrates the estimation of incident BC cases taking into account the pattern of mammography
use reported in the Health Surveys and the assumption of no overdiagnosis, for women born in 1950. The
highest age observed for the 1950 cohort was 54 years. Table 1) in the figure shows the number of BC cases
for 100,000 women at birth if the age at initial mammography use was z. Column 2−DA contains the
proportion of women that started annual screening at age z, Table 3) has been obtained by multiplying
Table 1) by column 2−DA and contains the number of BC cases from women that use mammography
with annual periodicity.
Table 4), column 5−DB and Table 6) in Figure 1 contain the same information for women that use
mammography with biennial periodicity and Table 7), column 8−Dbkg and Table 9) for women that do
not use screening mammography.
Adding the BC cases of Tables 3), 6) and 9), we obtain an expected cumulative incidence of CIe = 1573.9
in the age interval 40-54, per 100,000 women born in 1950.
To obtain the observed BC cumulative incidence per 100,000 women at birth, first we obtain the 5-year
age-specific incidence rates from the data (617.7, 768.3 and 1079.3 per 100,000 women in the age groups
40-44, 45-50 and 50-54 years, respectively). Then we multiply these rates by the probabilities of being alive
at each age (0.95, 0.94 and 0.93 for the three age-groups, respectively). Adding up these values we obtain
an observed cumulative incidence CIo = 2307.6.
Therefore, the estimated overdiagnosis for cohort 1950 in the age interval 40-54 years was:
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100× CIo − CIe
CIe
= 100× 2307.6− 1573.9
1573.9
= 46.6
E.2 Confidence intervals of the overdiagnosis estimates
Bootstrapping was used to obtain 95% confidence intervals of the overdiagnosis estimates. We repeated the
following sequence 1,000 times:
1. Draw a random sample with replacement of the residuals Zi =
Oi−Ei√
Ei
of the Poisson incidence model,
with Oi being the observed number of breast cancer cases and Ei the expected number in an age-
and cohort-group i.
2. Use the bootstrapped residuals (Zbi ) to create a new sample of count data using the expression
(Obi = max(0, Ei + Z
b
i
√
Ei)).
3. Use the values Obi to fit a new Poisson model for BC incidence and a corresponding background
incidence model. When fitting this model we allowed to vary the form of the fractional polynomial
for variable age and maintained the same powers for the other variables.
4. Follow the steps described in the Overdiagnosis estimation section to obtain a new overdiagnosis
estimate.
The 95% confidence interval limits were obtained using the percentiles 2.5 and 97.5 of the overdiagnosis
estimates.
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O U T C O M E S R E P O RT E D F R O M S U P P L E M E N TAT I O N
W I T H V I TA M I N D ( C H O L E C A L C I F E R O L O R
E R G O C A L C I F E R O L ) T O A D U LT C A N C E R PAT I E N T S .
A S Y S T E M AT I C R E V I E W
This is a systematic review of all the published clinical research out-
comes from cancer patients taking supplements of the inactive forms
of vitamin D (D2 or D3). A total of 21 original studies have been iden-
tified, including observational (retrospective and prospective) and ex-
perimental studies, but no randomized controlled trial assessing vita-
min D efficacy to improve outcomes in cancer patients. The vitamin
D dosages differed markedly. Furthermore, in the 99 studies report-
ing serum 25-hidroxivitamin D levels, the metabolite used to measure
vitamin D status, doses below 2,000 IU/day of either D2 or D3 were
insufficient to correct vitamin D deficiency.
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2 
Abstract 
 
Background 
A high prevalence of vitamin D deficiency among cancer patients has been already 
extensively reported. In the general population, vitamin D deficiency is a recognized risk 
factor for mortality for all causes despite normal circulating levels of the hormonal form 
of vitamin D (1,25-dihydroxyvitamin D), the most active endogenous metabolite of 
vitamin D. Undoubtedly, the safe supplementation with cholecalciferol (vitamin D3) or 
ergocalciferol (vitamin D2) directed exclusively to correct vitamin D deficiency should 
result in improvements in cancer outcomes. 
  
Aim 
To present all existing evidence from clinical studies on outcomes upon supplementing 
cancer patients with D2 or D3. 
 
Methods 
This is a systematic review of all published clinical research (only case reports were 
excluded) supplementing cancer patients with cholecalciferol or ergocalciferol. All 
studies using already active vitamin D metabolites (calcidiol, calcitriol or analogues) 
were excluded. The key words used for the literature search included synonyms of 
vitamin D and cancer in the title, and of supplement and patient either in the title or the 
abstract, in MEDLINE and SCOPUS. Review articles were not excluded to identify any 
missed study.  
 
Results 
A total of 541 studies were identified till the end of 2014. After reading the abstract, 509 
were excluded due to either the use of active vitamin D metabolites or the study of non-
adult cancers. The remaining articles included 21 original clinical studies and 10 
reviews. Ten (48%) were observational studies, one was a randomized controlled trial, 
and ten where non-controlled clinical trials. Most participants were either women with 
breast cancer (10 studies) or men with prostate cancer (4 studies). Even among studies in 
patients with the same cancer type, the dosage for vitamin D as well as the duration of 
supplementation differed markedly, thus precluding any meta-analysis on outputs. Doses 
lower than 1,000 IU/day were not effective to correct serum vitamin D concentrations, 
whereas higher doses did increase concentration to the normal range. 
 
Conclusion 
This review documents the need of well powered randomized controlled trials to obtain 
evidence based recommendations in support of the impact, or the lack of it, of the 
correction of vitamin D deficiency on clinical outcomes in cancer patients.. 
 
Keywords 
cancer; vitamin D; cholecalciferol; ergoferol 
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Introduction 
 
Background and rationale 
 
Cancer is a leading cause of disease and cause-specific death worldwide. According to 
data collected until 2012, the World Health Organization (WHO) estimated cancer 
incidence worldwide in 14.1 million and cancer-specific mortality in 8.2 million in 2012. 
Lung, female breast, colorectal and stomach cancers accounted for more than 40% of all 
incident cases diagnosed worldwide in 2012. In men, lung cancer was the most common 
cancer (16.7% of all new cases). Breast cancer was by far the most common cancer 
diagnosed in women (25.2% of all new cases). In terms of cancer-specific mortality, 
more than half of all cancer deaths each year are due to lung, stomach, liver, colorectal 
and female breast cancers. Given the morbidity and mortality of these malignancies, 
researchers are exploring new areas for prevention and treatment. Since vitamin D 
deficiency is a recognized risk factor for mortality for all causes, including cancer, in the 
general population, the safe and inexpensive correction of vitamin D deficiency through 
supplementation with cholecalciferol or ergocalciferol could help prevent/attenuate the 
devastating impact of cancer in the world. 
 
In fact, patients with cancer are highly vitamin D deficient. Data from observational 
clinical studies and small clinical trials support multiple health benefits from the local 
actions of the hormonal form of vitamin D upon the correction of serum vitamin D 
levels. The mechanisms underlying these benefits include the improvement of 
musculoskeletal function, reinforcement of anti-tumoral action with reduction of the 
severity of inflammatory responses by immune cells, antiproliferative and anti-
angiogenic properties. The benefits of vitamin D supplementation over treatment with 
active vitamin D metabolites, is the lower impact on hypercalcemia and 
hyperphosphatemia. The latter is a pro-aging factor that markedly enhances mortality in 
the general population. 
 
There are two safe and inexpensive approaches for vitamin D supplementation forms, 
cholecalciferol (D3) and ergoferol (D2). Although both metabolites elicit the same 
potency when administered daily, the half life of 25-hydroxyvitamin D2 is half of that of 
vitamin D3 and consequently, the frequency for non daily supplements should not extend 
longer than 14 days for D2, while large doses of cholecalciferol could be administered 
monthly. The increase in the number of publications on cancer and vitamin D increase 
led us to examine whether they could provide evidence of dosage, frequency of 
supplementation and impact on outcome in cancer patients. 
 
Objectives 
 
To identify and summarize all the outcomes published in observational and experimental 
clinical studies reporting the results obtained from the supplementation of cancer patients 
with D2 or/and D3. 
 
Methods 
 
The present study was designed as a systematic review of all published clinical research, 
including observational retrospective and prospective studies (in which participants are 
asked about the amount of vitamin D supplements that they usually take) and phase II 
4 
and III clinical trials (in which participants are prescribed with a certain amount of 
vitamin D).  
 
Only the clinical trials reporting results of supplementation with D2 or D3 to adult cancer 
patients were included in this systematic review. Therefore, children are excluded from 
the population of study, as well as the studies supplementing with other forms of vitamin 
D (calcifediol, calcitriol or analogues), due to the differences between cancers occurring 
in childhood and adulthood, or between the metabolism and actions of the inactive and 
active forms of vitamin D.  
 
The search strategy implemented in MEDLINE and SCOPUS included an advanced 
search with the four following key words “vitamin D”, “cancer”, “supplement”, 
“patient”, with synonyms and free suffixes and prefixes. The reviews identified by this 
search were exhaustively examined to ensure that all relevant references were included 
in this review.  
 
The final advanced search strategy used was: 
 
Pubmed: (*vitamin* D*[ti] OR *calciferol[ti] OR calcidiol[ti] OR calcife*[ti]) 
(*cancer*[ti] OR *onco*[ti] OR *carcino*[ti]) (patient*[tiab]) (*treat*[tiab] OR 
*drug*[tiab] OR *therap*[tiab] OR care[tiab] or supplement*[tiab] )  
 
Scopus: ( TITLE ( "*vitamin* D*"  OR  "*calciferol"  OR  "calcidiol"  OR  "calcife*" )  
AND  ABS ( patient* )  AND  TITLE ( *cancer*  OR  *onco*  OR  *carcino* )  AND  
ABS ( *treat*  OR  *drug*  OR  *therap*  OR care OR supplement* ) ) 
 
Results 
 
A total of 541 references till the end of 2014 were identified. After reading the abstract, 
the following exclusion criterion was applied: duplicate publications, scientific 
publications from basic rather than clinical research, clinical trials using vitamin D 
compounds different from vitamin D2 and D3, clinical studies supplementing with 
vitamin D2 and D3, but not reporting results from supplementation, case reports, and 
childhood cancer. Upon excluding 509 references, 21 original clinical studies (Table 1) 
were included in this systematic review. The 10 review articles were used to avoid 
missing any relevant clinical study. 
 
Ten (48%) of the 21 studies were observational, only one was a randomized controlled 
trial, and the other ten were non-controlled trials that had not been designed with the aim 
to assess outcomes after supplementation with vitamin D. The participants were mainly 
women with breast cancer (10 studies) or men with prostate cancer (4 studies). There 
were 3 studies with miscellanea of cancer types for the participants (Table 2), 2 studies 
with participants diagnosed of pancreatic carcinoma, 1 study with colorectal cancer 
patients and 1 with coetaneous T-cell lymphoma. In 6 studies, supplements combined 
vitamin D and calcium. In 5 studies, the amount of vitamin D (mainly D3, more 
frequently investigated than D2) was from 200 IU to 800 IU/day, and these studies 
demonstrated the uselessness of such a dose to correct serum vitamin D levels. The most 
recent publications were highly heterogeneous, some of them suggesting an initial high 
dose of 100,000 or 150,000 IU to correct vitamin D levels or to keep them in the normal 
range (>30 ng/mL).  
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Outcomes were reported upon such heterogeneous supplementation strategies that 
comparisons are not possible. Furthermore, the most common outcome reported is the 
proportion of patients that increased serum vitamin D levels above 30 ng/mL, correcting 
their deficiency. However, even this information was not provided in all the studies. 
Indeed, some studies only reported the change in the serum vitamin D concentration. In 
general, trials reported an increase in serum vitamin D till non-deficiency levels (>=20 
ng/dL) concentration when using a daily dose of at least 2,000 IU of D3 (table 3). Five 
studies reported an improvement in pain associated with vitamin D supplementation. 
One study reported a significant improvement in disease free survival for those taking 
vitamin D supplements.  
 
 
Discussion 
 
The most critical translational contribution of this review is the demonstration of the 
current need of well powered randomized controlled trials to obtain evidence based 
recommendations in support of the impact on clinical outcomes (or the lack of it) of 
appropriate supplementation strategies for the correction of vitamin D deficiency in 
cancer patients.  
 
The oldest study in this review by Van Veldhuizen et al, in 2000, was the first to suggest 
that cholecalciferol might have a therapeutic effect in men with advanced prostate 
cancer. Specifically, they supplemented 16 metastatic androgen-insensitive prostate 
cancer patients with 2,000 IU of vitamin D3 for 12 weeks to improve bone pain. At 
baseline, 8 (50%) of these patients had vitamin D levels below 20 ng/mL. After vitamin 
D supplementation, 4 men (25%) experienced improvement in pain scores and one 
showed a decrease in PSA from 99.2 to 55.3 ng/mL.  
 
Additional clinical research was conducted with lower and higher vitamin D doses. The 
review shows that lower doses are not sufficient to raise the serum vitamin D level to the 
normal range. The review published by Teleni et al at 2013, which included 7 of the 
studies of our review, suggests that natural sources of vitamin D or vitamin D “daily 
recommended allowance” are not enough for a cancer patient to reach adequate serum 
vitamin D concentrations. It was also clear from this review clear from this review the 
importance of personalizing vitamin D supplementation. The increase in serum 25-
hydroxyvitamin D in response to supplementation is not the same for all patients, even 
within a certain cancer type, with some individuals requiring a much higher dose of 
cholecalciferol or ergocalciferol to correct vitamin D deficiency.  
 
In Spain and the rest of Europe, the recommended dietary allowance (RDA) is 200 
IU/day (5 µg/day) for the general adult population. The European Food Safety Authority 
includes an exception to avoid bone loss (osteoporosis), where RDA is 800 IU/day from 
all sources. This review clearly illustrates that the supplementation of cancer patients 
following the approved recommendations will be useless..  
 
Given recognized benefits of the integrity of the vitamin D endocrine system in 
improving survival rates for all causes in the general population, and with an impact on 
key targets for the betterment of the quality of life of cancer patients as those of the 
relevance of the musculoskeletal function and the control of inflammation and the 
consequent pain, the manifest lack of randomized controlled trials in cancer is a major 
gap that could be filled safely and inexpensively by the scientific community to benefit 
6 
all cancer patients. 
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Study (Author Yr) Cancer Spetial characteristics Design S & A Groups 
Amir et al 2010 Breast Bone metastases+Bisphosphonates T2a 40 D3 + Ca 
Cantor et al 2014 Colon, lung, breast  OR 50 D3 
Cho et al 2013 Pancreas  OR 71 D (observed) 
Churilla et al 2012 Cancers* Consultation to radiation oncology Ta 118 D3 
Crew et al 2009 Breast adjuvant chemotherapy Tb 103 D3 
Davison et al 2012 Prostate Androgen deprivation therapy OP 51 Education on D3 + Ca 
Fakih et al 2012 Colorectal   Ta 50 D3 
Khan et al 2010 Breast Adjuvant letrozole Tb 51 D3 + Ca 
Klapdor et al 2012 Pancreas Exocrine pancreatic insuficiency Tb 51 D3 , individualized 
Marshall et al 2012 Prostate T1c or T2a and Gleason=6 Tb 48 D3 
Nogues et al 2010 Breast Early with aromatase inhibitors Tb 232 D3 + Ca 
Peppone et al 2011 Breast  OR 166 D2 or D3 
Rastelli et al 2011 Breast Aromatase inhibitors T2a 60 D3 + (Ca & D2 /placebo) 
Simmons et al 2009 Breast Bone Metastases+Bisphosphonates Tb 46 D3 in cases 
Talpur et al 2014 Lymphoma Cutaneous T-Cell lymphoma OP 156 D2 or D3 
Van Veldhuizen et al 2000 Prostate Metastasic T2b 16 D3 
Vashi et al 2010 Cancers**  OR 799 D3 
Waltman et al 2009 Breast Aromatase inhibitor OP 29 D3 + Ca 
Wang-Gillam et al 2008 Breast Bisphosphonates OR 120 D3 
Woo et al 2005 Prostate Survivors OP 15 D3 
Zeichner et al 2014 Breast Her2+ no mestastasic OR 134 D (observed) 
 
Note: OR: Observational and retrospective study; OP: Observational and prospective study; Tb: Clinical trial designed with a different  
primary outcome; Ta: Clinical trial with vitamin D correction as aim. S & A stands for supplemented and analyzed numer of patients. 
* 22% Breast; 21% Prostate; 14% Thyroid; 8% Lung; 5% Colorectal; 31% others. **22.7% Breast; 14.9% lung, 9.7 pancreas,  
9.3 colorectal, 8.4% prostate, 34.9% others. 
 
Table 1. Description of results for cancer patients supplemented with vitamina D (chole- or ergocalciferol) 
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 Women 
% 
Age median AJCC stage Compliance Vit. D duration 
Amir et al 2010 100% 55 Bone metastases 95.0% 4 mhs 
Cantor et al 2014 NA NA NA 100.0% 2 wks 
Cho et al 2013 46% 90% >=50 y I y II: 36%, III y IV: 64% NA(observational) NA 
Churilla et al 2012 50% 64 4% in situ; 26% in I; 32% in II; 18% in III; 16% 
in IV; 5% other 
NA NA (median 87 days between 
vitamin D determinations) 
Crew et al 2009 100% 43 34% in I; 60% in II and 6% in III 82.5% 1 yr 
Davison et al 2012 0% mean(SD) 
71.7(9.1) 
Non-metastatic 83.6% 1 yr 
Fakih et al 2012 44% 60 6%: II; 40%: III; 54%: IV 100.0% 6 mhs 
Khan et al 2010 100% 56 61.7%: I; 8.3%: II; 3.3%: III; 1.7%: IV; 25%NA 85.0% 16 wks 
Klapdor et al 2012 100% NA NA 72.8% 
supplemented 
Varying 
Marshall et al 2012 0% 65 T1c or T2a 92.3% 1 yr 
Nogues et al 2010 100% mean(SD) 
63.2(8.7) 
Early stage 95.7% 3 mhs 
Peppone et al 2011 100% NA 0-III stage 56.3% 8-16 wks 
Rastelli et al 2011 100% NA I-IIIB stage 78.3% 6 mhs 
Simmons et al 2009 100% NA NA NA NA 
Talpur et al 2014 NA NA NA NA NA 
Van Veldhuizen et al 2000 0% mean 67.5 IV 100.0% 12 wks after 4 wks placebo 
Vashi et al 2010 63% mean 55.4 0: 1.3%, I: 12.0%, II: 20.5%, III: 23.4%, IV: 
34.4%, indeterminate: 8.4% 
48.4% for 
25(OH)D<=32ng/mL 
median 10.9 wks (from 4 to 
97.1 wks) 
Waltman et al 2009 100% NA 0: 3.4%, I: 51.7%, II: 44.9% 92.5% adherence 24 mhs 
Wang-Gillam et al 2008 NA NA NA NA NA 
Woo et al 2005 0% Not reported T1C in 6.7%; T2A in 26.7%; T2B in 20%; T2C 
in 33.3%; T3 in 13.3% 
NA 8 mhs in median (from 4 to 
21) 
Zeichner et al 2014 100% mean(SD) 
53.0(12.1) 
100% non-metastasic NA Not reported (during adjuvant 
therapy) 
 
Table 2. Participants & follow-up of the studies 
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Study (Author Yr) Vit.D Supplement Results 
Amir et al 2010 10,000 IU D3 + 1000 mg Ca/day for 4 mhs 
No changes in bone resorption nor pain values; Decrease in number of sites of 
pain; Increase in serum Ca; Decrease in PTH; 5% hypercalcemia; 25(OH)D 
increased 69.5 : 162 nmol/L in 4 mhs 
Cantor et al 2014 
High dose of D3 on day 1 + 4,000 IU/day during 2 wks; 
D3 was 300,000 IU or 150,000 IU on day 1 depending 
on 25(OH)D <15 (n=18) or [15,30) ng/mL (n=32) No patient <20ng/mL after supplementation; 11% <30ng/mL; no toxicity 
Cho et al 2013 50,000 IU vit. D /wk x 10-12 wks 55%<30ng/mL within the supplemented Group 
Churilla et al 2012 50,000 IU D3/wk x 8wk for <30.0 ng/mL + 1,000 IU/day  
76(64.4%) with available posttreatment data. They changed mean serum 
25(OH)D: 20->35 ng/mL 
Crew et al 2009 400IU D3+1000mg Ca/day 60%<20; 29% in [20,30); 11% >=30. 
Davison et al 2012 1500 mg Ca + 20-25mcg D3 (800 IU-1,000IU)/day 
Inadequate vit. D intake (<20mcg) increased from 70.6 to 76.5%. Inadequate Ca 
intake (<1,200 mcg) decreased from 56.9% to 43.1%. 
Fakih et al 2012 2000 IU/day for 6 mhs 
Mean 25(OH)D increased from a mean of 17.5ng/mL to 31.6ng/mL at 3 mhs and 
33.8ng/mL at 6 mhs. At 3 mhs, 92% of chemotherapy free patients increased 
>=10ng/mL (vs. 39% with chemot.) 
Khan et al 2010 
1200 mg Ca+600IU D3 for 4 wks; If >40ng/mL, go on  
and if not, change to 50,000 IU D3 for 12 wks (13&42) 
100% with >40ng/mL; no toxicity; In n=42, higher frequency with no disability from 
joint paint, vasomotor and physical QoL (MEN-QOL) in women with >66ng/mL 
(median). No significant BFI 
Klapdor et al 2012 
From 1000IU/day to 20,000IU/day depending on the 
underlying disease and the mal-digestion/assimilation 
0% deficiency;15.7% in [20,30) in short-term supplementation; 4.2% in [20,30) in 
long-term supplementation with doses from 7,000 to 140,000 IU/wk to maintain in 
30-59 ng/mL 
Marshall et al 2012 4000 IU/day for 1 yr 
Change in the num. of + cores (biopsy): 55% decreased, 34% increased); No 
insufficient; No tox. 
Nogues et al 2010 
1000 mg Ca+800IU D3/day all; If body mineral 
densidy<-2 + Bisphosphonates; if 25(OH)D deficiency 
+ 16,000IU/2wks for 3 mhs 23.48% < 30ng/mL post supplementation 
Peppone et al 2011 
None (n=58) ,1000 IU/day (n=104) or >=50,000IU/wk 
(n=62) for 8-16 wks 
Significant increase in 25(OH)D for >=50,000IU/wk but not for 1,000 IU/day 
referred to no-suppl. 
Rastelli et al 2011 
1000mg Ca+400IUD3 for all. Randomized to placebo 
or 50,000IU/wk of D2 for 8wks if 25(OH)D in [20,30) 
or16wks if in [10,20) plus 50,000 IU/mth for 6 mhs 
11.5%>=30ng/mL in placebo group; 42.9% in D2 group. Pain scores were better 
for the D2 group after 2 mhs of treatment. Overalll, pain scores were better for the 
D2 group with <20ng/mL  
Simmons et al 2009 400 IU/day 18%<=40nmol/L; 62%(<=70nmol/L) after treatment 
Talpur et al 2014 D2 50,000 units biweekly or D3 1000 units/day orally 55(35%) corrected (>30 serum vit D) 
Van Veldhuizen et al 2000 2,000IU/day x 12 wks 25% improved pain & 37.5% improved strength 
Vashi et al 2010 8,000IU/day of Vit.D if <=32ng/mL 
Patients with prostate and lung cancer had the highest percentage of responders 
(25(OH)D> 32ng/mL in 70% and 69.2%) while those with colorectal and pancreas 
had the lowest (46.7%) 
Waltman et al 2009 1200 mg Ca+ 400 IU D3/day for 24 mhs 6.9%<20ng/mL;79.3% in [20,30). Vit D levels are related with pain 
Wang-Gillam et al 2008 <400 IU/day ;400-600 IU/day;>600 IU/day in n=32,41,8 In 81: 27.2%<20ng/mL;30.9% in [20-30) ng/mL 
Woo et al 2005 2000 IU/day of D3  Only results on PSA levels are reported. 
Zeichner et al 2014 60% <=1400IU/day 
8.2%<20ng/mL after supplementation (40.3% missing). In VitD, better DFS 
(HR=0.36) 
 
Table 3. Supplementation protocols and reported outcomes description 
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V I TA M I N D D E F I C I E N C Y A N D I T S A S S O C I AT I O N
W I T H FAT I G U E A N D Q U A L I T Y O F L I F E I N
A D VA N C E D C A N C E R PAT I E N T S U N D E R
PA L L I AT I V E C A R E . A C R O S S - S E C T I O N A L S T U D Y
This paper is currently under peer-review in Palliative Medicine.
This cross-sectional study presents a novel and significant associ-
ation between vitamin D deficiency and patient’s perceived fatigue,
physical functioning and quality of life. Fatigue was, in average, the
symptom with the highest adverse impact on daily life performance.
Currently, there is no effective therapeutic approach for decreasing fa-
tigue. Our findings suggest that a safe intervention to increase serum
levels of vitamin D may result in a significant improvement in quality
of life in advanced cancer patients.
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Abstract 
 
Background 
 
A normal vitamin D status is required for bones and muscles to maintain their structure and function, 
but it also contributes to the structural and functional integrity of other multiple physiologic systems 
in the body.  
 
Aim 
 
To assess the relationship of Vitamin D deficiency with health-related quality of life issues, fatigue 
and physical functioning in advanced cancer patients. 
 
Design 
 
This is a cross-sectional study. 
 
Patients/Settings 
 
Adults under palliative care, having a locally advanced or metastatic or inoperable solid cancer.  
 
Results 
 
Among 30 patients in palliative care with advanced solid cancer, 90% were vitamin D deficient. 
Serum Vitamin D concentration was positively correlated with patient-reported absence of fatigue 
(s=0.49), and physical and functional well-being (s=0.44 and =0.41, respectively, p<0.01). Fatigue 
was the symptom with the highest median impact on their lives and was the only one associated with 
serum vitamin D levels (p=0.031), with lower fatigue in patients with vitamin D concentrations in the 
third tertile. There was no evidence of a direct association between health-related quality of life and 
vitamin D status. 
 
Conclusion 
 
The 90% frequency of advanced cancer patients with vitamin D deficiency, together with the positive 
correlation of vitamin D status with the absence of fatigue and improved physical and functional 
well-being, points to vitamin D supplementation as a potential effective intervention to enhance the 
patient’s quality of life. 
 
Keywords 
 
advanced cancer; palliative care; vitamin D; quality of life; fatigue 
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Introduction 
 
Background and rationale 
 
Vitamin D is actually not a vitamin but a pro-hormone, as it is produced endogenously when 
ultraviolet rays from the sun light interact with the skin. It can also be obtained from fortified foods 
and a few unfortified foods but mostly, through supplementation. Vitamin D is a fat-soluble inactive 
compound and becomes biologically active through two hydroxylations, the first one occurring in the 
liver (converting vitamin D to 25hydroxyvitamin D, also called 25(OH)D or calcidiol) and the second 
one in the kidney where 25(OH)D is transformed into 1,25-dihydroxyvitamin D, also called 
1,25(OH)2D or calcitriol, the hormonal form of vitamin D and, consequently, the most active 
endogenous vitamin D metabolite [1]. 
 
Serum 1,25(OH)2D has a short half-life of 7-8 hours. Its synthesis is tightly regulated by serum 
parathyroid hormone, fibroblast growth factor 23 (FGF23), calcium and phosphate concentrations, 
and its circulating level does not typically decrease until vitamin D deficiency is severe [2,6], 
resulting in a bad indicator of the status of vitamin D [5]. In contrast, serum 25(OH)D has a relatively 
long circulating half-life of 15-18 days [5]. Because vitamin D conversion to 25(OH)D is loosely 
regulated, it better reflects the circulating level of vitamin D that a person obtains through the 
aforementioned sources [1]. Due to the difficulties in measuring vitamin D levels directly, 
measurements of 25(OH)D are used to estimate the status of vitamin D. The optimal serum 25(OH)D 
concentration is controversial but, for skeletal health, experts agree that levels lower than 20 ng/mL  
(it  is,  50 nmol/L)  are  suboptimal. 
 
Normal bone mineralization and growth are both promoted by a normal vitamin D status, which 
protects children from developing hypocalcemic tetany and rickets, and adults from osteomalacia and 
osteoporosis [1,2]. Normal vitamin D is also required to maintain the integrity of muscle structure 
and function [7]. Furthermore, Indeed, vitamin D is involved in the modulation of cell growth 
(proliferation, differentiation, and apoptosis) in multiple cell types, neuromuscular and 
immunological functions, and in reducing inflammation and inflammation-driven multiorgan damage 
[1,3,4]. Despite epidemiologic data suggesting that vitamin D may have a protective effect against 
colon cancer, the evidence is not as strong for its protective effects against prostate, breast, and 
cancers at other sites [1]. Most of these non-classical adverse effects of vitamin D deficiency are 
mediated by the defective local conversion of circulating 25(OH)D to 1,25(OH)2D by bone, muscle, 
and immune cells, and not by low circulating 1,25(OH)2D, as serum 1,25(OH)2D  remains within the 
normal range until 25(OH)D falls below 4 ng/ml. 
 
Based upon: 1) the significant fatigue, physical and functional impairment in patients with advanced 
cancer, 2) the very limited therapeutic measures currently available to reduce them, and 3) the 
benefits of a normal vitamin D status on the functional integrity of multiple physiologic systems in 
the body, we hypothesized that a significant proportion of patients with advanced cancer in palliative 
care is vitamin D deficient, ie 25(OH)D <20 ng/ml, and that there is an association between serum 
vitamin D levels and both the patient’s self-assessment of quality of life, and the patient’s capacity to 
perform daily living activities. 
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Objectives 
 
The objectives are to estimate the proportion of patients with advanced cancer in palliative care who 
present with serum vitamin D deficiency and to establish the relationship between serum vitamin D 
levels and the patient-perceived quality of life, as well as their physical condition, functional capacity 
and fatigue. 
 
 
Methods 
 
Study design and setting 
 
The present study was designed as a cross-sectional study in palliative care cancer patients. 
 
Participants were in- and out-patients who satisfied the inclusion and exclusion criteria and were 
examined at the Hospital Universitari Arnau de Vilanova, in Lleida, Spain, from March 2013 to 
August 2014. 
 
Participants 
 
Eligible patients were adults under palliative care because of a locally advanced or metastatic or 
inoperable solid cancer, upon signing an informed consent. Since this study evaluates patient-
perceived outcomes, patients having a Karnofsky < 30%, a cognitive deterioration (more than 5 
mistakes in Pfeiffer test), or suffering from significant pain, dyspnoea, nausea or vomiting (more than 
6 out of 10 in the corresponding Numerical Rating Scale 0:10) were excluded. Additional exclusion 
criteria included pregnant or breast-feeding females, patients undergoing severe liver or renal (GFR < 
60) failure, or those who had received chemo or radiation therapy within the last 3 weeks prior to 
inclusion, or with the possibility of initiating a new cycle of chemo or radiation therapy within a 
period of 6 weeks after their inclusion. 
 
 
 
Variables 
 
Data collection was performed prospectively after approval of the study protocol by the hospital’s 
ethics committee. 
 
Vitamin D 
 
Quantification of serum levels of 25-hydroxyvitamin D (25(OH)D) were measured in ng/mL using 
the Chemoluminescence-Immuno assay on the Liaison XL Analyzer (DiaSorinOR ) in the Central 
Laboratory at the HUAV. 
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Primary and secondary end-points 
 
Health-related quality of life (HRQoL) was considered the primary outcome and was assessed 
using the global health status/quality of life item from EORTC QLQ-C15-PAL, a questionnaire 
developed for palliative care cancer patients. Scores range from 0 (poor) to 100 (excellent). 
 
Cancer-related fatigue was considered a secondary outcome and was assessed using the fatigue 
subscale of the FACT questionnaire. This is a widely used 13-item fatigue subscale where each 
item is a five-point Likert self-reported scale ranging from 0 =”not at all” to 4 = ”very much so”. 
The total score varies from 0 = ”worst condition” to 52 = ”best condition”. 
 
Other patient-reported secondary outcomes included rates on: 1) the impact of fatigue, pain, 
dyspnoea, constipation, appetite loss, nausea/vomiting and insomnia, 2) physical and emotional 
functioning, 3) physical and functional well-being, and 4) functional capacity in the activities of 
daily living. The rates on the impact of symptoms were assessed using the questionnaire EORTC 
QLQ-C15-PAL, with scores ranging from 0 (none) to 100 (the highest) for negative impact on daily 
life. This questionnaire also includes the assessment of physical and emotional functions, both 
expressed as scores from 0 (poor) to 100 (excellent). The physical and functional well-being were 
assessed using the FACT questionnaire with scores varying from 0 = ”worst condition” to 28 = 
”best condition”. The addition of these two scores to the FACT estimation of fatigue is known as 
”Trial Outcome Index”. Finally, the patient-reported functional capacity in the activities of daily 
living was assessed using the Barthel’s Scale, an ordinal scale that measures performance from 0 
(completely dependent) to 100 (independent). 
 
Clinician-reported patient’s performance status was assessed with the Karnofsky and the Palliative 
Performance Scales (PPS). Both provide a score from 100 to 0, where 100 indicates no evidence of 
disease (normal performance) and 0 indicates death. 
 
 
 
Covariates 
 
Patients’ socio-demographic characteristics (age, gender and educational level), anthropometric 
characteristics (height, weight, body mass index, and tricipital skinfold thickness), primary tumour 
(coded according to the ICD 10), tumour stage, and standard serum chemistries (25(OH)D, 
hemoglobin, leukocytes, lymphocytes, platelets, triglycerides, total cholesterol, total proteins, 
albumin, liver transaminases ALT and AST, C-reactive protein, phosphorus, creatinine, calcium), 
and urinary chemistries (creatinine, calcium and microalbumin). 
 
Sample size 
 
Sample size was established to estimate a correlation coefficient between 25(OH) D serum levels 
and self-perceived quality of life equal to or greater than 0.5, with 95% confidence (bilateral) and 
80% statistical power. Based on these considerations, a minimum of 30 patients is required. 
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Statistical methods 
 
A descriptive analysis of the study sample was performed using the usual summary measures for 
qualitative and quantitative variables. The proportion of vitamin D deficiency, with 95% confidence 
interval was estimated with the exact Binomial distribution. The relationship of 25(OH)D serum 
levels with the quantitative end-points was assessed graphically (scatterplots) and by estimating the 
Spearman’s rank correlation coefficients. Associations between quantitative end-points and 
25(OH)D were also checked by grouping patients according to 25(OH)D tertiles. These 
associations were assessed graphically (boxplots) and statistically by using the Kruskal Wallis test. 
A significance level of 5% and the statistical software R [11] were used. 
 
 
Results 
 
Participants 
 
Table 1. Description of the patients (N=30) 
 Summary measure 
Men 23 (76.7%)           
Age (years) 60.5 [55.5;71.0] 
Educational level (n=27):          
Illiterate   2 (6.7%)   
Primary-High school   22 (83.3%)   
College   3 (10.0%)   
BMI (kg/m2) (n=27) 24.3 [21.1;27.7] 
Tricipital skinfold thickness (cm) (n=28) 1.5 [  1.0;  2.0] 
Malignant neoplasma of:  
Hypopharynx (C13)   2 (  6.7%)   
Esophagus (C15)   2 (  6.7%)   
Colon (C18)   4 (13.3%)   
Rectum (C20)   1 (  3.3%)   
Anus / anal canal (C21)   1 (  3.3%)   
Gallbladder (C23)   1 (  3.3%)   
Pancreas (C25)   2 (  6.7%)   
ill-defined digestive organs (C26)   1 (  3.3%)   
Larynx (C32)   1 (  3.3%)   
Bronchus and lung (C34)   5 (16.7%)   
Breast (C50)   1 (  3.3%)   
Corpus uteri (C54)   1 (  3.3%)   
Uterus (C55)   1 (  3.3%)   
Prostate (C61)   3 (10.0%)   
Kidney(C64)   2 (  6.7%)   
Brain (C71)   2 (  6.7%)   
Tumour stage:          
3   2 (  6.5%)   
4   28 (93.5%)   
Note: Qualitative characteristics are described as absolute number and relative frequency (%). Quantitative 
characteristics are described as median [interquartile interval] 
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The participants’ characteristics are shown in Table 1. A total of 30 patients was consecutively 
included after checking eligibility criteria. The study participants were primarily men (76.7% ), had 
low educational levels (60.1% ), were in average 63.3 (SD=10.97) years old and had an average 
body mass index of 24.4 (SD=5.07). The distribution of primary tumours was heterogeneous, being 
the most frequent in the digestive system (14, 46.7%), followed by those from the respiratory (6, 
20.0%), reproductive (5, 16.7%), urinary (2, 6.7%), and nervous (2, 6.7%) systems. Patient’s 
disease stage was, mainly, metastasic. Regarding blood test results, patients had clinically 
significant low levels of serum total protein, hemoglogin and percentage of lymphocytes and high 
levels of C-reactive protein, with medians and interquartile intervals of 5.6 [5.2;6.2] g/dL, 10.4 [9.3, 
11.7] mg/dL, 11.0% [6.1%, 13.4%] and 22.9 [7.05;63.8], respectively (Table 2). 
 
Table 2. Chemistries 
 
Patients’ 
summary measures 
Hospital 
reference values 
Patients within 
normal range 
S.Creatinine (mg/dL) 0.72 [  0.57;  0.83] 0.5-1.4 80% 
S.Calcium (mg/dL) 8.44 [  7.94;  8.83] 8.6-10.2 40% 
S.Phosphorus (mg/dL) 2.97 [  2.37;  3.44] 2.7-4.5 60% 
S.Total cholesterol (mg/dL) 160.5 [131.3;184.8] 150-220 50% 
S.Triglycerides (mg/dL) 144.0 [  94.3;203.0] 50-200 73% 
S.Total proteins (g/dL) 5.61 [  5.19;  6.19] 6.6-8.7 7% 
S.Albumin (g/dL) 3.10 [  2.83;  3.38] 3.4-5.2 27% 
S.Aspartate Transaminase (U/L) 19.0 [  15.3;  26.5] 5-38 87% 
S.Alanine Transaminase (U/L) 18.5 [  14.0;  26.5] 5-40 87% 
S.C-reactive proteína (mg/L) 22.9 [    7.1;  63.8] 0-6 20% 
S.25(OH)D (ng/mL) 8.5 [    6.7;  12.6] 30-100 3% 
U.Creatinine (mg/dL) (n=19)  47.8 [  32.5;  84.6] 39-259 63% 
U.Calcium (mg/dL) (n=19) 6.60 [  3.10;  9.65] 5.2-35.7 63% 
U.Microalbumin (mg/L) (n=18) 5.77 [    1.9;  22.3] 0.01-20 61% 
S.Leukocytes (x10x9/L) 10.2 [    7.9;  13.2] 4.8-10.8 47% 
S.Hemoglobin (gr/dL) 10.4 [    9.3;  11.7] 13.0-18.0 17% 
S.Platelets (x10x9/L) 275.0 [232.3;346.0] 140-450 93% 
S.Lymphocytes (%) 11.0 [    6.1;  13.4] 17-51 17% 
S.Lymphocytes (x10x9/L) 1.09 [  0.78;  1.46] 0.9-5.2 60% 
Note: Summary measures represent median [interquartile interval]. References values are the normal range used 
at the hospital.  
 
 
 
Vitamin D distribution 
 
The vast majority of patients showed vitamin D deficiency, and the three subjects with levels over 
20 ng/dL stand out as outliers, with a clearly asymmetric distribution. The proportion of patients 
with vitamin D deficiency was 90%, with an estimated 95% confidence interval of IC95%[73%, 
98%]. The two tertiles were 7.6 and 10.5 ng/dL. Based on these values, the sample was partitioned 
into patients with values lower than 8 (n=12), from 8 to values lower than 11 (n=9), and patients 
with concentrations of 11 or higher (n=9). 
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Clinician-reported performance status 
 
Both performance status scales scores, KPS and PPS, showed a median of 60.0, and interquartile 
intervals of [50.0;60.0] and [52.5;60.0], respectively. Thus, an average participant required 
occasional assistance but was able to care for most of their personal needs (Table 3). 
 
Table 3. Physical performance and patient-reported outcomes 
 
Patients’    
summary measures 
Score range, 
best score 
KPS (Karnofsky performance scale), from 0 to 100, + 60.0 [50.0;60.0] [0;100], 100 
PPS (Palliative performance scale), from 0 to 100, + 60.0 [52.5;60.0] [0;100], 100 
Barthel, from 0 to 100, + 85.0 [61.3;98.8]  [0;100], 100 
PWB (Physical well-being), + 15.0 [11.5;20.0] [0;  28],   28 
FWB (Functional well-being), + 10.0 [6.00;12.0] [0;  28],   28 
FS (FACIT Fatigue score), + 20.3 [14.0;34.8] [0;  52],   52 
TOI (PWB+FWB+FS), + 45.0 [32.3;68.3] [0;108], 108 
Pain impact, - 41.7 [4.17;95.8]  [0;100],     0 
Dyspnoea impact, - 33.3 [0.00;66.7] [0;100],     0 
Insomnia impact, - 33.3 [0.00;66.7] [0;100],     0 
Appetite loss impact, - 33.3 [0.00;91.7] [0;100],     0 
Constipation impact, - 33.3 [8.33;100]  [0;100],     0 
Fatigue impact, - 66.7 [47.2;100]  [0;100],     0 
Nausea/Vomiting, - 0.00 [0.00;16.7] [0;100],     0 
Physical functioning, + 33.3 [13.3;60.0] [0;100], 100 
Emotional functioning, + 50.0 [41.7;79.2] [0;100], 100 
Overall quality of life, + 50.0 [33.3;62.5] [0;100], 100 
Note: Values represent median [interquartile interval]. Symbols + and – indicate that high scores mean better or 
worse health status, respectively, in reference to the patient measured outcome. 
 
 
 
Patient-reported outcomes 
 
Patient-reported outcomes are summarized in Table 3. Overall quality of life (QL) showed a 
median of 50.0, with quartiles 33.3 and 62.5. Emotional functioning (EF) showed the same median 
score but more variability. In contrast, physical functioning (PF) showed much lower scores. 
The median performance of daily living activities according to Barthel scale (BS) was estimated to 
be 85 out of 100, with first and third quartiles 61.3 and 98.8, denoting autonomy. 
The median of patient’s fatigue (FS) assessment (using FACT-F subscale) was 20.3 out of 52 (52 
being equivalent to absence of fatigue). Physical and functional well-being (PWB and FWB 
respectively) were scored with a median of 15.0 and 10.0, respectively, out of 28 (28 being the 
value denoting the best condition). 
 
The patient’s impact of symptoms score ranged from 0 (none) to 100 (the highest impact). Among 
all the symptoms, fatigue demonstrated the highest impact, with a median 41.7, followed by pain, 
dyspnoea, sleep, appetite loss and constipation, with a median of 33.3. By contrast, more than 50% 
of patients reported no impact of nausea/vomiting. 
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Vitamin D relationships 
 
Table 4. Association between serum 25(OH)D concentrations and patient’s age, body mass index, tricipital skin 
fold and chemistries.  
 
Spearman 
rho 
25(OH)D 
<8 
25(OH)D 
[8.0,11.0) 
25(OH)D 
>=11 
K-W 
 
Age (years) -0.13 (0.480) 70.0 [58.5;76.8] 59.0 [55.0;62.0] 58.0 [54.0;71.0] 0.180 
BMI (kg/m2) -0.14 (0.490) 24.3 [20.9;26.4] 26.0 [24.2;29.3] 23.6 [20.4;26.5] 0.596 
Tricipital skinfold thickness (cm) 0.25 (0.207) 1.30 [1.03;1.58] 1.10 [1.00;2.00] 1.90 [1.00;2.10] 0.471 
      
S.Creatinine (mg/dL) -0.07 (0.718) 0.78 [0.58;1.01] 0.66 [0.50;0.77] 0.72 [0.59;0.78] 0.657 
S.Calcium (mg/dL) 0.40 (0.031) 8.04 [7.60;8.58] 8.51 [8.40;8.83] 8.71 [8.33;8.84] 0.127 
S.Phosphorus (mg/dL) 0.41 (0.023) 2.52 [2.13;3.00] 3.03 [2.59;3.31] 3.35 [3.22;3.94] 0.071 
S.Total colesterol (mg/dL) -0.13 (0.481) 160.5 [145.3;180.8] 175.0 [142.0;185.0] 130.0[116.0;188.0] 0.452 
S.Triglycerides (mg/dL) -0.43 (0.019) 162.5[126.0;224.5] 180.0[122.0;208.0] 93.0 [83.0;113.0] 0.040 
S.Total proteins (g/dL) 0.23 (0.212) 5.57 [4.99;6.23] 5.68 [5.52;6.10] 5.50 [5.40;6.53] 0.674 
S.Albumin (g/dL) -0.02 (0.911) 3.15 [2.90;3.43] 2.90 [2.80;3.10] 3.20 [2.80;3.30] 0.647 
S.Aspartate Transaminase (U/L) -0.24 (0.210) 21.0 [14.8;25.8] 20.0 [18.0;37.0] 16.0 [15.0;17.0] 0.100 
S.Alanine Transaminase (U/L) -0.01 (0.957) 17.5 [14.0;20.5] 27.0 [20.0;64.0] 14.0 [12.0;25.0] 0.013 
S.C-reactive proteína (mg/L) 0.05 (0.782) 22.9 [6.35;30.8] 23.0 [9.30;68.2] 14.7 [9.00;134.0] 0.963 
U.Creatinine (mg/dL) 0.02 (0.951) 61.4 [32.5;74.8] 62.5 [42.9;87.8] 45.9 [22.4;69.9] 0.579 
U.Calcium (mg/dL) 0.25 (0.297) 1.80 [1.15;7.95] 6.60 [4.94;10.7] 8.00 [5.70;9.65] 0.239 
U.Microalbumin (mg/L) -0.33 (0.188) 22.8 [15.3;39.4] 11.3 [1.89;42.0] 2.32 [1.88;4.00] 0.118 
S.Leukocytes (x10x9/L) -0.17 (0.361) 11.31 [8.11;15.8] 9.86 [8.78;11.4] 9.28 [4.55;13.2] 0.619 
S.Hemoglobin (gr/dL) 0.20 (0.298) 10.55 [9.60;11.3] 9.70 [8.50;11.6] 11.1 [10.2;13.7] 0.251 
S.Platelets (x10x9/L) -0.34 (0.069) 288.0 [248.0;325.0] 350.0 [230.0;381.0] 233.0[180.0;279.0] 0.256 
S.Lymphocytes (%) -0.08 (0.677) 9.95 [6.55;13.43] 11.8 [8.10;12.20] 11.0 [4.10;13.70] 0.792 
S.Lymphocytes (x10x9/L) -0.15 (0.433) 1.25 [0.89;1.43] 0.95 [0.78;1.45] 0.87 [0.44;1.46] 0.829 
Note: S and U indicates serum and urinary chemistries. Spearman’s rank correlation coefficient with serum 25(OH)D 
concentrations and its p-value in brackets are shown in the second column. Columns from third to fifth represent the 
median, [first; third quartiles] for each of the 25(OH)D tertiles. The last column shows the Kruskal-Wallis test p-value for the 
differences between the three groups for each of the analyzed parameters. 
 
 
 
The results of blood and urine tests showed some statistically significant relationships with serum 
25(OH)D concentration (Table 4). Specifically, serum phosphorus and calcium showed positive 
and statistically significant Spearman’s rank correlations of 0.41 and 0.40 respectively whereas 
triglycerides showed a negative and statistically significant Spearman’s rank correlation of -0.43. 
All these correlations were confirmed when partitioning participants according to the tertiles of 
serum vitamin D levels. In addition, a significant association was found for serum Alanine 
Transaminase concentration, with significantly higher values for the second tertile of 25(OH)D. 
 
Clinician-reported performance status showed a positive Spearman’s rank correlation with serum 
25(OH)D concentration according to both performance scales (0.37 for KPS and 0.40 for PPS). 
Both correlations were confirmed when partitioning participants according to the tertiles of serum 
vitamin D levels (Table 5). 
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Table 5. Association between serum 25(OH)D concentrations and either performance status or patient’s reported 
outcomes. 
Table 5 
Spearman 
rho 
25(OH)D 
<8 
25(OH)D 
[8.0,11.0) 
25(OH)D 
>=11 
K-W 
 
Barthel,+ 0.34 (0.069) 65.0 [53.8;85.0] 90.0 [85.0;95.0] 100.0 [70.0;100] 0.083 
KPS (K. performance scale),+ 0.37 (0.043) 50.0 [50.0;60.0] 60.0 [50.0;60.0] 60.0 [60.0;70.0] 0.092 
PPS (P. performance scale),+ 0.40 (0.031) 55.0 [50.0;60.0] 60.0 [60.0;60.0] 70.0 [60.0;80.0] 0.031 
PWB (Physical well-being),+ 0.44 (0.014) 14.5 [10.5;15.3] 13.0 [10.0;14.0] 22.0 [20.0;24.0] <.001 
FWB (Functional well-being),+ 0.41 (0.026) 6.50 [4.00;10.5] 7.00 [6.00;11.0] 12.0 [11.0;18.0] 0.021 
FS (FACIT Fatigue score),+ 0.49 (0.006) 17.0 [8.8;23.4] 17.0 [14.0;22.0] 38.0 [28.0;43.0] 0.004 
TOI (PWB+FWB+FS),+ 0.50 (0.005) 36.8 [25.5;47.0] 37.0 [32.0;45.0] 75.0 [55.0;82.0] 0.001 
Pain impact,- 0.08 (0.679) 33.3 [0.00;87.5] 83.3 [66.7;100] 16.7 [0.00;33.3] 0.204 
Dyspnoea impact,- -0.14 (0.474) 33.3 [0.00;75.0] 50.0 [0.00;75.0] 33.3 [0.00;66.7] 0.906 
Insomnia impact,- -0.14 (0.461) 33.3 [0.00;66.7] 33.3 [0.00;66.7] 0.00 [0.00;33.3] 0.380 
Appetite loss impact,- -0.22 (0.233) 50.0 [25.0;75.0] 33.3 [0.00;100] 0.00 [0.00;33.3] 0.312 
Constipation impact,- 0.03 (0.863) 33.3 [25.0;100] 66.6 [33.3;100] 33.3 [0.00;100] 0.581 
Fatigue impact,- -0.32 (0.087) 94.4 [58.3;100] 88.9 [66.7;100] 55.6 [33.3;66.7] 0.031 
Nausea/Vomiting,- -0.39 (0.031) 16.7 [0.00;25.0] 0.00 [0.0;16.7] 0.00 [0.00;0.00] 0.025 
Physical functioning,+ 0.36 (0.052) 16.7 [6.67;36.7] 33.3 [20.0;46.7] 73.3 [33.3;93.3] 0.037 
Emotional functioning,+ 0.07 (0.712) 50.0 [41.7;70.8] 41.7 [41.7;50.0] 66.7 [50.0;83.3] 0.482 
Overall quality of life,+ 0.13 (0.489) 41.7 [29.2;54.2] 33.3 [16.7;50.0] 50.0 [50.0;66.7] 0.108 
Note: Spearman’s rank correlation coefficient with serum 25(OH)D concentrations and its p-value in brackets are shown 
in the second column. Columns from third to fifth represent the median [first; third quartiles] for each of the 25(OH)D 
tertiles. The last column shows the Kruskal-Wallis test p-value for the differences between the three groups for each of 
the analyzed parameters. 
 
Among the patient-reported outcomes, those positively correlated with 25(OH)D were FS (0.49), 
PWB (0.44) and FWB (0.41). These results were confirmed when partitioning participants 
according to the tertiles of serum vitamin D levels (Figure 1). A statistically significant negative 
Spearman’s rank correlation was observed with nausea/vomiting (-0.39), although it was due to the 
high score reported by patients in the first tertile of serum 25(OH)D. Statistically significant 
associations were also found for the Barthel index, also due to the low score reported by patients in 
the first tertile of serum 25(OH)D, and for the physical functioning (PF) score and the fatigue 
symptom impact. Both of the latter associations (lower fatigue impact and higher PF) showed a 
significantly better score for the third tertile. No statistically significant association was found for 
the overall quality of life or other symptoms impact assessments or emotional functioning. 
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Figure 1. Association between the tertiles of serum 25(OH)D, in ng/dL, and quality of 
life-related parameters. Boxplot analysis of the association between tertiles of 25(OH)D in 
the X-axis and patient-reported: a) FACIT-Fatigue subscale score, from 0 to 52, with 52 
denoting the best condition; b) FACIT-Physical Well-Being, from 0 to 28, with 28 denoting 
the best condition; c) FACIT-Functional Well-Being, from 0 to 28, with 28 denoting the best 
condition; d) QLQ-Fatigue Impact, from 0 to 100, with 0 denoting no impact of fatigue on 
daily life; e) QLQ-Physical Functioning, from 0 to 100, with 100 denoting excellent physical 
functioning, and f) QLQ-Overall quality of life, from 0 to 100, with 100 representing a 
palliative care patient with an excellent quality of life. 
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Discussion 
 
This study shows that vitamin D deficiency is highly present in patients in palliative care with an 
advanced solid cancer, who are not severely disabled but are no longer candidates to receiving 
chemo or radiotherapy. Vitamin D deficiency was estimated to be 90%, with a 95%CI of [73%, 
98%]. Two significant positive Spearman correlations were found with serum calcium and 
phosphorus, both of them expected given vitamin D induction of intestinal calcium and 
phosphate absorption. A significant negative Spearman correlation was found with triglyceride 
levels, a finding in agreement with the randomized controlled trial by Muñoz-Aguirre et al [12] in 
2014, demonstrating a significant reduction in triglyceride levels after supplementation with 
vitamin D to postmenopausal women with diabetes. The self-assessment of symptoms placed 
fatigue as the one with the greatest impact in their lives, above pain, dyspnoea, sleeplessness, 
appetite loss, constipation, and nausea/vomiting. Fatigue was also the only symptom with a 
perceived impact significantly correlated with serum 25(OH)D concentrations, which in turn was 
significantly correlated with the physician’s assessment of patients’ performance and with patient-
reported physical functioning, perceived fatigue as well as with physical and functional well-being. 
A significant association of 25(OH)D levels with patient-reported overall quality of life or with 
emotional functioning could not be established. 
 
The main limitation of our findings is the scarce number of patients. Furthermore, given the high 
heterogeneity of primary tumors included in the study, it is not possible to conduct subanalyses for 
each primary tumour type. This subanalysis would be important to rule out that the particular type 
of primary tumor has a direct impact on both the severity of  vitamin D deficiency or even on the 
patient´s perceived quality of life. Nevertheless, this analysis is beyond the scope of this study.  
 
Another limitation is the single-center setting of the patients, which precludes any further 
extrapolation of our findings, since geographical locations markedly affects both dietary vitamin D 
intake, and more importantly, sun exposure, both with a great influence on serum 25(OH)D 
concentrations. However, the geographical influence may be negligible in advanced cancer patients 
under palliative care as sun exposure is contraindicated before receiving chemo or radiotherapy and 
also because of their low regular food intake, as they are often malnourished. 
 
There is great variability in the estimated occurrence of vitamin D deficiency among cancer 
patients. The most recent estimate from Brisbane, Australia, in patients with non-haematological 
cancer was of 44%. However, the report included patients undergoing both oncological and 
palliative care [8]. Among advanced cancer patients, estimates of vitamin D deficiency (defined as 
<20 ng/dL) vary between 47%[9] and 64%[10].  
 
The recent report of a significant positive correlation (measured by Kendall’s rank correlation test) 
between serum vitamin D levels with the Australia-modified Karnofsky Performance Status 
(AKPS)  [8], supports  our finding of  significant positive correlations of 0.37 with KPS and 0.40 
with PPS and serum 25(OH)D levels, as estimated by Spearman’s rank correlation coefficients.  
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In conclusion, our study underscores the importance of correcting vitamin D deficiency in cancer 
patients under palliative care, as patients with higher serum 25(OH)D levels showed significantly 
higher scores in patient’s reported FS, PF, PWB, and FWB scales, and very low scores of fatigue 
impact when compared with patients with lower serum 25(OH)D concentrations. To our knowledge 
this is the first study to report that fatigue is the symptom with the highest impact in advanced 
cancer patients in palliative care. The translational relevance of this finding is high as it suggests 
that vitamin D supplementation could  reduce fatigue and improve physical and functional status. 
Although a direct relationship between serum vitamin D levels and quality of life could not be 
demonstrated, it would be reasonable to speculate that, by reducing fatigue, the health-related 
quality of life, as perceived by these patients, could be improved. Undoubtedly, only a randomized 
clinical trial would address this critical issue. To this end, a randomized clinical trial, with EudraCT 
number 2013-003478-29, has been designed. 
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T H E E F F E C T O N Q U A L I T Y O F L I F E O F V I TA M I N D
A D M I N I S T R AT I O N F O R A D VA N C E D C A N C E R
T R E AT M E N T ( V I D A FA C T S T U D Y ) : P R O T O C O L O F A
R A N D O M I S E D C O N T R O L L E D T R I A L
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According to the NIH Office of Dietary supplements (USA), vita-
min D (cholecalciferol) is related to “resistance to chronic diseases
(such as cancer and cardiovascular diseases), physiological parame-
ters (such as immune response or levels of parathyroid hormone),
and functional measures (such as skeletal health, physical perfor-
mance and falls)”. All of these relationships underscore the potential
benefits of cholecalciferol supplementation in cancer. This is the first
study designed to obtain conclusive evidence on the effect of chole-
calciferol in advanced cancer patients. The main goal is to assess the
effects of cholecalciferol supplementation on patient’s perceived qual-
ity of life. Cholecalciferol impact on fatigue and physical performance
will also be assessed, as well as the cost-utility of cholecalciferol sup-
plementation.
Patients satisfying the inclusion criteria will be randomly assigned
to receive either cholecalciferol or placebo upon signing an informed
consent. Eligible patients will be adults under palliative care for hav-
ing a locally advanced or metastatic or inoperable solid cancer. Among
exclusion criteria will be having a Karnofsky < 30%. This is random-
ized triple-blind placebo-controlled multicenter trial. The randomiza-
tion will involve a computer-generated randomization procedure cen-
tralized by the coordinating center. The assigned treatment will be
allocated by the hospital’s pharmacy service in order to warrant that
neither patients nor their health care providers know their assigned
group. Cholecalciferol (4000IU/day) or placebo will be added to pal-
liative care treatment starting at day 14 and continued up to day 42,
with programmed outpatient follow-up visits every 14 days.
67

The effect on quality of life of vitamin
D administration for advanced cancer
treatment (VIDAFACT study): protocol
of a randomised controlled trial
Montserrat Martinez-Alonso,1,2 Adriana Dusso,3 Gemma Ariza,4 Maria Nabal5
To cite: Martinez-Alonso M,
Dusso A, Ariza G, et al. The
effect on quality of life of
vitamin D administration for
advanced cancer treatment
(VIDAFACT study): protocol
of a randomised controlled
trial. BMJ Open 2014;4:
e006128. doi:10.1136/
bmjopen-2014-006128
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006128).
Received 16 July 2014
Revised 12 November 2014
Accepted 14 November 2014
1Ciències Mèdiques
Bàsiques, Universitat de
Lleida, Lleida, Spain
2Biostatistics and
Methodological Support,
IRBLLEIDA, Lleida, Spain
3Experimental Nephrology,
IRBLLEIDA, Lleida, Spain
4Rehabilitation Unit, Hospital
Universitari Arnau de
Vilanova, Lleida, Spain
5Palliative Care Supportive
Team, Hospital Universitari
Arnau de Vilanova, Lleida,
Spain
Correspondence to
Montserrat Martinez-Alonso;
montserrat.martinez@cmb.
udl.cat
ABSTRACT
Introduction: Vitamin D is related to resistance to
chronic diseases, physiological parameters and
functional measures. All of these relationships
underscore the potential benefits of cholecalciferol or
D3 (nutritional vitamin D) in cancer. This is the first
study designed to obtain conclusive evidence on the
effect of cholecalciferol in advanced patients with
cancer. The main goal is to assess its effects on the
patient’s perceived quality of life. Cholecalciferol’s
impact on fatigue and physical performance, as well as
its cost utility, will also be assessed.
Methods and analysis: A randomised triple-blind
phase II/III placebo-controlled multicentre trial has
been designed. Patients satisfying the inclusion and
exclusion criteria will be randomly assigned to receive
cholecalciferol or placebo. Eligible patients will be
adults with a locally advanced or metastatic or
inoperable solid cancer in palliative care, who have
given signed informed consent and have matched
inclusion and exclusion criteria. The randomisation will
be based on a computer-generated procedure and
centralised by the pharmacy service of the coordinating
centre. The assigned treatment will be administered by
the hospital’s pharmacy to conceal group allocation for
patients and healthcare providers. Cholecalciferol
(4000 IU/day) or placebo, starting at day 15 and
continuing up to day 42, will be added to palliative care
treatment. Outpatient visits will be scheduled every
14 days.
Ethics and dissemination: Ethical approval was
received from the Medical Ethical Commitee of the
HUAV (CEIC-1169). Participants and their families will
receive the research findings which will also be
disseminated on local and national media, presented at
national and international meetings of the specialty,
and published in peer-reviewed scientific journals.
Trial registration number: EudraCT: 2013-003478-29.
INTRODUCTION
Background and rationale
Cancer-related fatigue is the most common
symptom in patients in palliative care with an
overall prevalence of 90% at terminal stages.1
However, cancer-related fatigue cannot be
easily diagnosed, since it may be masked by
pain, dyspnoea or nausea.2 It often becomes
apparent once it compromises basic daily life
activities.3 Additionally, there are also subject-
ive, psychological and emotional compo-
nents of the impact of lack of strength on
each individual, which can be appropriately
assessed by currently available questionnaires
which measure the patient’s perception of
the impact of fatigue on his/her quality of
life.4 5
The pathogenesis of cancer-related fatigue
is multicausal and involves physiological and
biochemical disorders directly associated
with tumour progression, severe adverse
effects resulting from cancer treatment, as
well as physical and psychological stress,
anaemia, lack of exercise, chronic pain and
severe uncontrolled symptoms.6 7
At present, a variety of interventions have
been studied with reportedly small but sig-
niﬁcant beneﬁts such as drug therapy,8–10
which are not free of adverse effects.
Psychosocial and physical interventions on
fatigue intensity are also available for patients
with cancer.11 However, in patients in pallia-
tive care, recommendations for therapy are
scarce. Functional rehabilitation12 should be
Strengths and limitations of this study
▪ At least a clinically relevant improvement in the
quality of life is expected for oncological patients
with no possibility of curable treatments.
▪ It is a multidisciplinary approach to patient care
which includes coordination with physiatrists in
functional rehabilitation.
▪ Cost utility analysis of vitamin D supplementation
will allow informed decision-making.
▪ Potential limitations are that the amount of sun
exposure, although expected to be low for
patients with advanced cancer in palliative care,
has not been taken into account.
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tailored to each patient to help maintain a relatively
active daily life. The goal is not to recover a speciﬁc level
of activity, but to maintain physical endurance so that
rest or inactivity will not reduce muscle reserve.
Vitamin D is a fat-soluble vitamin present in only a few
foods, but which can be obtained from sun exposure
and supplements in its biologically inert form. It must
undergo two hydroxylations in the body for activation.
First, the liver converts vitamin D to 25-hydroxyvitamin
D (25(OH)D), and afterwards the physiologically active
1.25-dihydroxyvitamin D (1.25(OH)2D) is produced
mainly by the kidneys.
A recently published review13 supports numerous
reports delineating the multiple mechanisms underlying
vitamin D prosurvival actions experimented with at the
laboratory. Their ﬁndings show that vitamin D deﬁciency
results in a defective control of: (1) Cell growth causing
hyperproliferative disorders, genomic instability, Tumour
necrosis factor Alpha Converting Enzyme (TACE)-driven
metastasis, exacerbated growth and immune escape; and
accelerated progression of cancer lesions;14–17 (2) DNA
repair mechanisms causing age-associated disorders and
resistance to therapy in cancer;16 18 (3) Muscular weak-
ness and impaired neuromuscular function;19 20 (4)
Musculoskeletal pain derived from cancer treatment;21
(5) The immune system causing increased antigenicity in
antigen presenting cells, reduced content of T-regulatory
lymphocytes, systemic inﬂammation and multiple organ
damage, as well as a higher propensity for autoimmune
disorders;15 19 (6) The integrity of the FGF23/klotho
responsible for the antiageing properties of klotho in the
kidneys, in protecting the vasculature from atheromatosis
and calciﬁcation, and as a tumour suppressor and
protector from the onset of resistance in cancer treat-
ment;22–24 (7) The renin-angiotensin system to prevent
hypertension, renal and cardiovascular damage due to
excessive oxidative stress;25 26 (8) Acquisition of athero-
thrombotic phenotype of circulating monocytes-
macrophages and increased severity of atherosclerotic
lesions;27 (9) Podocyte function to protect from protein-
uria and proteinuria-induced cardiovascular lesions.28 29
When no curable treatment is possible, palliative care
is directed towards minimising symptoms, relieving suf-
fering and bringing patients to the best possible
health-related quality of life (HRQoL). Avoiding the tox-
icity associated with some palliative treatments is a must
in these patients. There is an urgent need to develop
new interventions in this population based on current
evidences, namely: (1) The strong epidemiological asso-
ciation between vitamin D deﬁciency and the high risk
of mortality from all causes in the general population15
and speciﬁcally from cancer;30 31 (2) The high fre-
quency of vitamin D deﬁciency in patients with cancer,
estimated to be between 47%32 and 88%;33 (3) The
anticancer, antiageing, antipain, immunomodulatory
and the protective renal, cardiovascular and neuromus-
cular properties of a normal vitamin D status;15 19 34 35
and (4) The signiﬁcant 11% reduction in all cause
mortality estimated for D3 by combining all randomised
controlled trials.30 We present a clinical trial designed to
obtain, for the ﬁrst time, evidence-based recommenda-
tions on the efﬁcacy of vitamin D3 supplementation, a
safe, non-costly therapeutic strategy, in improving phys-
ical performance, decreasing fatigue and increasing
HRQoL in patients with advanced cancer in palliative
care.
OBJECTIVES
The primary objective of this study is to evaluate the efﬁ-
cacy of the administration of vitamin D3 to enhance
patient-reported HRQoL.
The secondary objectives of this study are: (1) To
evaluate the efﬁcacy of the administration of vitamin D3
for enhancing physical performance, decreasing per-
ceived fatigue and achieving serum levels of 25(OH)D
above 30 ng/mL; (2) To evaluate the effect on tumour
biomarkers; (3) To explore the relationship between
vitamin D treatment compliance and 25(OH)D levels;
(4) To explore the relationship between 25(OH)D levels
and renal function; (5) To explore the dose–response
relationship in the group of patients with vitamin D3 for
the main outcome; (6) and to assess the cost utility of
the proposed administration of vitamin D3.
METHODS AND ANALYSIS
The tolerable upper intake level (UL=4000 IU/day or
100 µg/day) has already been established by the
European Food Safety Authority for the adult popula-
tion.36 However, there is a need for a proof of concept
trial to be conducted in patients with advanced cancer
in palliative care to gain preliminary data on the safety
and efﬁcacy of high doses (at UL) of vitamin
D. Therefore, a phase II proof of concept study is
planned to obtain reliable data to support a phase III
conﬁrmatory trial, within a randomised controlled trial
with a placebo two-stage adaptive design.
Trial design
A randomised triple-blind phase II/III placebo-controlled
multicentre trial has been designed. The randomisation
will be based on a computer-generated procedure centra-
lised by the pharmacy service of the coordinating hospital
in order to ensure the required treatment allocation con-
cealment. Serum levels of vitamin D will be not available
for the patients or their physicians to preserve treatment
allocation concealment. Randomisation will be stratiﬁed
by primary solid tumour type in a 1:1 ratio. In a proof of
concept trial (phase II or stage 1), patients will be
assessed after the ﬁrst 14 days of treatment about self-
perceived changes in HRQoL. The study includes a ﬁrst
interim analysis similar to a futility test to discontinue the
trial, and reject vitamin D3, if no better outcome is
obtained when compared to the placebo group.
Otherwise, it will continue to Phase III (stage 2), which is
planned to establish the efﬁcacy in improving and
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maintaining HRQoL as well as the safety of the treatment
with UL of vitamin D over placebo for 28 days (till day 42
from enrolment). This study will assess the efﬁcacy of
vitamin D when administered in combination with the
usual palliative care and functional rehabilitation.
Study setting
Phase II of the study will take place at Hospital
Universitari Arnau de Vilanova (Lleida, Spain). For
phase III of the study, three additional Spanish hospitals,
Duran i Reynalds (Barcelona), La Paz (Madrid) and
Virgen de la Macarena (Sevilla), will participate.
Patients
Eligible patients will be adults with a locally advanced or
metastatic or inoperable solid cancer in palliative care on
signed informed consent. Exclusion criteria will be
having a Karnofsky <30%, being pregnant or breastfeed-
ing females, undergoing severe liver or renal (glomerular
ﬁltration rate <60 ml/min) failure, having a cognitive
deterioration (more than 5 mistakes in the Pfeiffer test),
suffering from signiﬁcant pain, dyspnoea, nausea or
vomiting (more than 6 out of 10 in the corresponding
Numerical Rating Scale 0:10), hypercalcaemia
(> 10.5 mg/dL), having received chemotherapy or radi-
ation therapy within the past 3 weeks prior to inclusion,
or having the possibility of initiating a new cycle of
chemotherapy or radiation therapy within a period of
6 weeks after their inclusion date.
A prescreening day is scheduled for each adult patient
with a locally advanced or metastatic or inoperable solid
cancer in palliative care who did not present any known
reason to be excluded. On that day, a blood test will be
ordered (since results should be available on the screen-
ing day for the complete assessment of exclusion cri-
teria) and a visit with the physical rehabilition medical
doctor will be scheduled for the same day.
On the screening day, those patients satisfying inclu-
sion and exclusion criteria will be provided with com-
plete information about the study and enrolled into the
study pon signed informed consent.
Intervention
Vitamin D3 supplements of 4000 IU/day (UL) or
placebo will be added to palliative care treatment on day
14 after enrolment and continued up to day 42.
Outpatient visits will be scheduled every 14 days.
Supportive evidence for the UL established dose36 is
provided by randomised controlled studies in which this
quantity or higher was administered to various popula-
tion groups for up to 12 months without evidence of
persistent hypercalcaemia or hypercalciuria.
Palliative care treatment will be standardised among
participating physicians to ensure comparable proce-
dures on symptoms control (pain, nausea, vomiting,
constipation, diarrhoea, lack of appetite, shortness of
breath, cough and dry mouth).
Functional rehabilitation will be coordinated by the
rehabilitation doctor at each participating hospital from
day 0. On that day, there will be an evaluation of the
clinical and functional status (weakness, effort tolerance,
mobility, functional performance and independence in
activities of daily living), neuro-orthopaedic disorders,
orthopaedic aids necessary to improve the functionality
and individualised physical therapy to perform. Three
additional sessions will be scheduled before day 14 to
work in the following basic protocols: Assisted and free
active physical therapy; Respiratory physiotherapy;
Rehabilitation of trunk balance in sitting and standing;
Re-education in walking; Energy saving measures, and
teaching family involvement. Any requirement for add-
itional measures of rehabilitation will be speciﬁcally
noted. Leaﬂets containing advice and recommended
exercises for functional rehabilitation will be provided to
all participating patients and their families.
OUTCOMES
Primary outcome
Change in patient self-reported HRQoL is the primary
outcome. It will be assessed using the European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C15-PAL,37 a questionnaire developed
for patients with cancer in palliative care. It includes
rates on: pain, physical function, emotional function,
fatigue, global health status/quality of life, nausea/
vomiting, appetite, dyspnoea, constipation and sleep. Its
scale rating global health status/quality of life using a num-
bered scoring scale from 1 or very poor to 7 or Excellent is
the primary outcome. An anchor question approach is
included in order to establish ranges of scores reﬂecting
patient self-assessment of changes in perceived HRQoL
(as an approach to minimal important difference
assessment).
Since patients with advanced cancer in palliative care
can undergo rapid health deterioration (within a few
days), primary as well as secondary outcomes will be
recorded at baseline and on the allocation day (14 days
after enrolment) in order to assess intrapatient variabil-
ity occurring before any intervention. After starting the
intervention, primary and secondary outcomes will be
collected on days 28 and 42 from enrolment day (after
14 days and 28 days of taking vitamin D or placebo).
Secondary outcomes
Change in cancer-related fatigue is the second most
important outcome, and will be assessed with the fatigue
subscale of the Functional Assesment of Cancer
Therapy:Fatigue (FACT-F) questionnare.38 FACT-F is a
widely used 13-item fatigue subscale where each item is
a ﬁve-point Likert self-report scale ranging from 0=‘not
at all’ to 4=‘very much so’. The total score varies from
0=‘worst condition’ to 52=‘best condition’.
Change in functional capacity is another important
secondary outcome and will be assessed using the
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Barthel Scale,39 an ordinal scale that measures perform-
ance in activities of daily living, as well as the Karnofsky
and the Palliative Performance Scale (PPS) scores,40 41
which are used to quantify patients’ performance status.
All of them provide a score from 100 to 0, where 100
indicates no evidence of disease (normal performance)
and 0 indicates death.
Other secondary outcomes include changes in serum
levels of 25-hydroxyvitamin D, changes in tumoural bio-
markers, adherence to the randomised intervention
(deﬁned by the proportion of compliance with the ran-
domised intervention out of the total 28 days), renal
function and cost utility analyses. Utilities will be based
on the patient self-reported HRQoL measured by
EuroQoL (EQ-5D; 3 L). This questionnaire assesses ﬁve
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) to deﬁne the health state
of patients. Each health state will be translated in the
corresponding valuation by applying the Spanish
general population utility weights, resulting in valuations
from 1 (optimal health) through 0 (as bad as death) to
negative values (worse than death). Direct costs will be
collected in both groups.
Sample size
The research team considers that a 15% difference is
clinically relevant and that differences below 15% will
not sufﬁce to demonstrate the clinical signiﬁcance of
the effect of supplementation with vitamin D on quality
of life. Therefore, this study is designed to detect differ-
ences of 15% or more in the proportion of patients with
improved HRQoL between the groups. Error probabil-
ities of α and β to 0.05 and 0.2, respectively, for a unilat-
eral contrast with a 1:1 allocation are ﬁxed for sample
size calculations.
The phase II sample size is designed to control early
stopping probability based on the exact binomial distri-
bution (Simon, 1989) on optimal two-stage designs and
ﬁxed to at least 28 patients per group (optimal design
for the ﬁrst stage). The trial will be stopped if the
number of patients that improve is not higher in the
intervention group than in the control group.
The total sample size for this study (adding phases II
and III) is computed as the minimal number of patients
per group to detect differences from 15%, even in the
case of maximal requirements that would be having pro-
portions of improvement in HRQoL close to 50%.
Therefore, with proportions of improvement in HRQoL
of 42.5% for the placebo group and 57.5% for the
vitamin D group, and using the same error probabilities
in a unilateral contrast, a minimum of 137 patients per
group (a total of 274 patients enrolled) are estimated as
the minimum sample size required by applying the arcsi-
nus approximation. Since twice this improvement could
be observed in the vitamin D group, an interim analysis
is scheduled at the end of treatment for the ﬁrst 43
patients per group (phase II patients included) in order
to minimise the number of patients in the placebo
group. If the difference in the proportion of patients
with minimally improved HRQoL is twice the expected
15% in favour of vitamin D3, the trial will be stopped for
ethical reasons for the beneﬁt of the patients in the
placebo group. In other words, the second interim ana-
lysis is planned with a stopping rule so that if the
improvement difference is 30% or greater, all the partici-
pants will beneﬁt. Figure 1 summarises this study design.
Assignment of interventions
The randomisation process will be centralised at the
Pharmacy Service of the Hospital Universitari Arnau de
Vinalova. The Pharmacy Service will be the responsible
for randomising and blindly assigning vitamin D3 or
placebo to each patient, stratiﬁed by the primary
tumour and blocking it to ensure the same number of
patients in each intervention. Drug or placebo formula-
tion, labelling and allocation will be performed by the
pharmacist, who will create an identiﬁer for each
patient, independently from the order of entry into the
study. The matching of each patient identiﬁer with its
allocated intervention will be saved in an independent
database for the exclusive use of the pharmacist or the
External Safety Monitoring Committee until the end of
the study.
Data collection and management
Figure 2 summarises the data collection and manage-
ment description that is detailed below.
Data collected exclusively at baseline (day 0)
The inclusion and exclusion criteria checklist and base-
line information will be also collected including sociode-
mographical data (age, sex, education), anthropometric
data (height), clinical data (primary tumour, stage and
treatment), as well as treatments that may interact with
vitamin D (antiepileptics, antihypercholesterolaemic,
certain diet drugs and corticosteroids).
Data collected at all visits (days 0, 14, 28 and 42)
Collection will include: anthropometric data (weight,
body mass index, triceps skinfold); palliative care treat-
ments (cachexia, pain,...); functional capacity (Barthel,
Karnofsky, PPS); cancer-related fatigue (FACT-F
Figure 1 Trial design.
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subscale); and quality of life (EORTC QLQ C15 PAL
and EQ-5D). Biochemical data will be separated into
one part available during the study for the patient and
the physician (PCR, total protein, serum albumin, trigly-
cerides and cholesterol (total, low-density lipoprotein,
high-density lipoprotein)) and another available during
the study only for the external Data Monitoring
Committee (25-hydroxyvitamin D, serum calcium and
urinary calcium).
Data collected in the postallocation visits (days 28 and 42)
Patient assessment of change from the start of treatment
will be collected in response to the question: Please indi-
cate whether there has been any change in your health
related quality of life from the start of treatment by
choosing one of the following options: −3, very much
worse; −2, much worse; −1, slightly worse; 0, no change;
1, a little better; 2, much better; 3, very much better. An
at least minimal improvement is deﬁned for patients
with an answer from 1 to 3 to this question.
Reported compliance per day starting on day 15 will
be also collected.
Most people are not expected to suffer from any side
effect, unless they take more than the prescribed
amount of vitamin D. Hypercalcaemia and patient
assessment of weakness, fatigue, drowsiness, headache,
loss of appetite, dry mouth, metallic taste, nausea or
vomiting are the adverse events listed in the bibliog-
raphy. Adverse events will be collected using an ordinal
scale of four categories for each one: ‘No (0 points)’,
‘Mild (1 points)’, ‘Moderate (2 points)’ and ‘Severe
(3 points)’. All adverse events happening postinterven-
tion (from 15th to 48th day) will be recorded through-
out the study, registering: the adverse event name,
starting and ending dates, frequency, severity, intensity,
relationship to study drug, action taken and resolution.
Any suspected unexpected serious adverse reaction
(SUSAR) will be reported to the Spanish Agency
(AEMPS). An SUSAR is deﬁned as any adverse reaction
to vitamin D which shows a reasonably and unexpected
causal relationship, whose nature, severity or outcome is
not consistent with the summary of the characteristics of
the technical data and that produces death, endangers
the patient’s life immediately, produces a persistent or
signiﬁcant disability, requires or prolongs hospitalisation,
or becomes a signiﬁcant danger that is comparable to
the above criteria.
Statistical analysis
For the ﬁrst interim analysis, only the number of
patients with at least minimally improved HRQoL will be
compared, with no statistical test to base the decision to
stop. For the second interim analysis, a difference
between response rates of 30% or higher will be used to
make the decision to stop. At the end of the study, a
descriptive univariate analysis of each group will be per-
formed, followed by a comparison between groups to
check if randomisation produced comparable groups in
each potential confounder. Bivariate analyses will use
the Mann-Whitney or χ2 test for quantitative or qualita-
tive variables, respectively. In case of differences, analysis
of minimally improved HRQoL by logistic regression will
be performed adjusting for them. For differences
between groups in longitudinal measurements (such as
chemistries), linear and non-linear mixed-effect models
will be used. Additionally, for the intervention group
(patients treated with vitamin D), longitudinal measures
of serum vitamin D and renal function will be related by
ﬁtting mixed effects linear models. Main outcomes will
be analysed by intention to treat. A longitudinal analysis
of treatment compliance (cumulative dose in both
periods of 14 days) will be performed in relation to
serum vitamin D levels as well as an analysis per protocol
to look at dose–response effects. Finally, a cost utility
analysis of the intervention with cholecalciferol will be
performed. For each patient, quality-adjusted life years
Figure 2 VIDAFACT participant
timeline.
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will be calculated as the area under the EQ-5D utility
curve. Since patients with missing values from question-
naires are likely to be worse than those with the available
measurements, the missing outcomes will be imputed
using non-linear regression models. A p<0.05 will be
established as statistically signiﬁcant. R software will be
used.42
ETHICS AND DISSEMINATION
Any amendment will be immediately communicated to
both agencies. All participants will provide signed
informed consent and their conﬁdentiality will be guar-
anteed by encoding all personal information. Insurance
will cover any unexpected damage attributable to partici-
pation in the study.
Ethical implications
An external Safety Monitoring Committee has been
created, comprised of one physician external to the
study from each of the participating hospitals. They will
be responsible for monitoring participants’ calcium and
vitamin D levels during the study in order to ensure the
patients’ safety and allocation concealment. The
research team has no economical interest in favour of or
against vitamin D supplementation. Its only interest is to
provide evidence as to whether vitamin D supplementa-
tion is beneﬁcial or not for patients with advanced
cancer in palliative care. Criteria to stop after any of the
two planned interim analyses are clearly stablished in
the study protocol. After each interim analysis, blindly
performed by the statistician of the research team, the
pharmacy service will assess the results of interim ana-
lyses in relation to the stopping rules established in the
protocol and with their exclusive knowledge of the inter-
vention groups. They will be responsible for communi-
cating the end or the continuation of the study based
on the criteria established in the study protocol to the
research team. The two interim analyses and the phase
II/III study design are part of this protocol to minimise
the use of time and patients required to demonstrate
whether, as hypothesised, there is a clinically signiﬁcant
beneﬁt from the use of vitamin D in patients with
advanced cancer in palliative care. The size of the group
randomly assigned to placebo is minimised during the
study and, if the effect of vitamin D interventions
become conclusive,this group will also be supplemented
with vitamin D.
Dissemination policy
Given this project’s scientiﬁc and social interest, its
results will be locally and internationally disseminated in
congresses, scientiﬁc papers and the media.
DISCUSSION
The potentially high scientiﬁc and social interests of this
project, fully based on the premise that ‘When no
curable treatment is possible, palliative care should be
directed towards minimizing symptoms, relieving suffer-
ing and bringing patient to the best possible health
related quality of life’, can be summarised as follows:
Scientiﬁcally:
1. The results of this safe, cost-effective intervention
with vitamin D supplementation in patients in pallia-
tive care research would be, to the best of our knowl-
edge, the ﬁrst attempt to conclusively address
whether the quality of life for these patients could
also improve from the prosurvival properties of a
normal vitamin D status, as reported not only in
healthy individuals but also in those with diabetes,
hypertension, cardiovascular disease, autoimmune
disorders, tuberculosis, kidney disease and cancer.
2. This work could provide evidence-based recommen-
dations for the efﬁcacy of vitamin D supplementation
to patients in palliative care in improving their
quality of life. Such a ﬁnding could be immediately
incorporated into clinical practice due to its low cost
and lack of toxicity. Furthermore, if conﬁrmed, these
ﬁndings should provide a solid basis for the design of
prospective, well-powered clinical trials directed at
customising vitamin D supplementation regimens in
order to expedite the correction of vitamin D deﬁ-
ciency in treatment-resistant patients and, more
importantly, ensure the fast improvement of their
quality of life.
3. It could help initiate new lines of research on the
pathogenesis of cancer-related fatigue to prevent its
onset at early stages and attenuate its progression in
cancer.
4. It could bring basic and clinical research together in
the arena of advanced cancer.
5. The most optimistic outcome would be to change the
‘current paradigm’ for patients in palliative care from
a state of ‘no curable treatment possible’ to a vitamin
D healing transition making the patient eligible for a
new customised cancer therapy with vitamin D as a
coadjuvant therapy.
Socially:
1. For the individual: The possibility of giving a patient
in palliative care a safe, non-costly, and evidence-
based effective option to maintain their quality of
life, and the hope that they could eventually become
eligible to restart cancer therapy for a cure is
invaluable.
2. For the community: This is research with a poten-
tially high clinical relevance, completely independent
from the interests of the pharmaceutical industry,
whose results could beneﬁt patients in palliative care
even in underdeveloped countries with the poorest
of healthcare systems.
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Part III
D I S C U S S I O N

7
A B O U T C U R R E N T R E S U LT S
This thesis has studied two specific aspects of quality of life related
to cancer, one impacting on women attending breast cancer screening,
and the other on individuals with advanced cancer in palliative care.
7.1 overdiagnosis of breast cancer
Overdiagnosis affects those women who, in the absence of symptoms,
undergo a screening test for breast cancer that detects a tumor which
would never have become symptomatic, otherwise. These women are
diagnosed and treated for asymptomatic tumors with no progressive
potential, and they undergo both unnecessarily invasive tests and in-
tensive treatments. Our model-based estimates of overdiagnosis in
Catalonia for the birth-cohorts born from 1935 to 1950 showed an in-
creasing trend from 0.4% to 46.6%. These estimations are associated
with the increased use of screening mammography that began in the
1990s in Catalonia.
Kalager et al (Kalager 2012) published a registry-based study that
estimated the overdiagnosis of breast cancer in Norway. They com-
pared the incidence of invasive breast cancer from 1996 to 2005 in
counties where the screening program was implemented with the
incidence in counties where the program was not yet implemented.
Two approaches were used with this data, both different from our
approach. The estimated rate of overdiagnosis attributable to the pro-
gram was 18% to 25% (P < 0.001) and 15% to 20% (P < 0.001) de-
pending on the approach used. Thus, in accordance with our results,
mammography screening entails a substantial amount of overdiagno-
sis.
Carter et al (Carter 2015) conducted a systematic review of the
methodology used to quantify and monitor overdiagnosis in cancer
in 52 studies, including our study. From the four main estimation
methods used, including randomized trials, model-based, pathologi-
cal and imaging, and ecological and cohort studies, the most appro-
priate were ecological and cohort studies, because of their possibility
to monitor overdiagnosis over a long period of time. To monitor pro-
grams is important to maximize the benefits of cancer screening while
minimizing harm and cost. The main criticism of the estimates based
on mathematical models is the uncertainty about mean sojourn time
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in the preclinical state, a parameter that must be included as an input
in the model. Sensitivity analyses are required to test the dependabil-
ity of results from these assumptions. According to this review, only
5 from a total of 21 model-based studies performed a sensitivity anal-
ysis.
Our own results of overdiagnosis in breast cancer underscore the
importance of striving to meet the ethical responsibility to adequately
inform women and help them make screening decisions according to
their informed preferences. In this context, Hersch et al (Hersch 2015)
investigated whether including information about overdetection of
breast cancer in a decision aid would help 50 year old women to
make an informed choice about breast screening. They concluded that
women can incorporate overdetection information into their reason-
ing about screening, thereby improving the quality of their decisions.
7.2 quality of life in advanced cancer
Despite the accumulated epidemiological evidence of the high inci-
dence of vitamin D deficiency in oncological patients, a systematic
review of all the available literature reports on outcomes from ei-
ther cholecalciferol or ergoferol supplementation to cancer patients
demonstrated the lack of well powered, randomized controlled trials
evaluating the efficacy of vitamin D supplementation in correctiong
vitamin D deficiency or in improving outcomes.
The few original clinical studies reporting outcomes in cancer pa-
tients supplemented with vitamin D2 or D3 are very heterogeneous
in the vitamin D daily dose used and also in the duration of treatment.
A common finding is that the correction of vitamin D deficiency in
cancer requires at least of 2,000 IU/day, a dose much higher than the
recommended dietary intake. Some researchers support the use of
an initial dose of 100,000 IU or 150,000 IU on the first day, followed
by 4,000 IU daily, afterwards, to expedite the acquisition of normal
vitamin D levels (Cantor 2014). The work by Klapdor et al (Klap-
dor 2012) is the only publication reporting that doses were personal-
ized to reach and maintain serum vitamin D concentrations over 30
ng/mL in pancreatic cancer patients. Indeed, dose requirements var-
ied as much as from 7,000 IU/week to 140,000 IU/week depending
on the patient.
The results of the cross-sectional study presented in this thesis can
be considered a proof of concept to conduct the VIDAFACT clinical
trial, directed to assess the relationship between correcting serum vi-
tamin D levels (measured by 25(OH)D concentrations) through daily
7.2 quality of life in advanced cancer 81
supplementation with 4,000 IU of cholecalciferol and the quality of
life, fatigue and physical and functional performance. Indeed, 90% of
the examined 30 advanced cancer patients in palliative care showed
vitamin D deficiency. Even a healthy individual with vitamin D defi-
ciency can suffer from bone pain and muscle weakness depending on
the severity and the duration of the deficiency. In the cross-sectional
study, serum vitamin D concentration was positively correlated with
patient-reported absence of fatigue, and physical and functional well-
being. From the assessment of the symptoms impact on the perceived
well-being, fatigue presented the highest median impact on their lives,
rating above pain, dyspnoea, constipation, appetite loss, nausea/vom-
iting and insomnia. Fatigue was also the only symptom associated
with serum vitamin D levels, with lower fatigue in patients with vita-
min D concentrations in the upper tertile.
Although in the cross-sectional study there was no direct associa-
tion between health-related quality of life and vitamin D status, the
observed high impact of fatigue on patients’ lives, above that of pain,
and its correlation with serum vitamin D concentrations, it is reason-
able to postulate that increasing serum vitamin D levels to the normal
range could further attenuate fatigue, increase muscle strength and
improve the quality of life of cancer patients in palliative care.
This thesis includes the design of VIDAFACT, a randomised triple-
blind phase II/III placebo-controlled multicentre trial consisting of
a safe, inexpensive supplementation with vitamin D to patients in
palliative care. The main goal is to conclusively address whether the
quality of life of these patients could improve as a result of the re-
ported prosurvival properties of a normal vitamin D status. Addi-
tional goals include:
• To provide evidence-based recommendations of the efficacy of
vitamin D supplementation in improving the quality of life to
patients in palliative care;
• To provide solid basis for the design of prospective, well-powered
clinical trials directed to customise vitamin D supplementation
regimens to expedite the correction of vitamin D deficiency in
treatment-resistant patients;
• To initiate new lines of research on the pathogenesis of cancer-
related fatigue to prevent its onset at early stages and attenuate
its progression;
• To bring basic and clinical vitamin D research together into the
advanced cancer arena;
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• To assess whether vitamin D supplementation can change the
‘current paradigm’ for patients in palliative care from ‘no cur-
able treatment possible’ to being eligible for a new customised
cancer therapy with vitamin D as a coadjuvant therapy.
The achievement of the main goal has high individual and social
interests. For the individual, there will be the possibility of receiving
a safe, non-costly evidence-based effective option to maintain their
quality of life. For society in general, the low cost of cholecalciferol,
which makes it independent from the interests of the pharmaceutical
industry, offers the possibility of helping advanced cancer patients in
palliative care even in countries with the poorest economy.
One of the critiques to the protocol of the VIDAFACT is the use of
one dose of cholecalciferol of 4,000 IU/day for 4 weeks rather than
the recommended higher dosages, as high as 40,000 IU of D3 per
day and for a longer follow-up of at least 1 year, and preferably 3.
The rationale to choose this treatment regimen is the vulnerability of
advanced cancer patients in palliative care and also the current up-
per intake level of vitamin D for healthy adults, established by the
European Food Safety Authority. Although it might be possible to
use higher doses up to 10,000 IU daily without any risk for the pa-
tient, as happens in patients with multiple sclerosis, the safety of such
therapeutic strategy has not been tested in patients with advanced
cancer under palliative care. Considering their severe weakness and
poor general health, it might be counterproductive. Furthermore, can-
cer often causes hypercalcaemia of malignancy, and hypercalcemia is
the main adverse effect of high vitamin D supplementation, with un-
doubtedly would aggravate the existing hypercalcemia.
Regarding the issue of extending the follow up to 1 year, preferably
3, the main limitation is the frailty of patients with advanced cancer
in palliative care, which makes them unable to attend the outpatient
clinic or unwilling to undergo blood tests. Furthermore, they are ex-
pected to survive no longer than one year. Valuable interventions for
these patients are those that will offer improvements in the quality of
life, shortly after the initiation of the therapeutic strategy, which was
the rationale to examine the efficacy of vitamin D supplementations
within four weeks. The 4,000 IU/day may not suffice to correct vitam-
ina D deficiency in 28 days. Nevertheless, in our cross-sectional study,
the reduction of the perception of fatigue was observed for values be-
low the normal range.
A main limitation is that a randomized clinical trial makes impossi-
ble to personalize dosage to correct vitamin D deficiency, but it could
help identify a target concentration in circulation necessary to im-
prove outcomes. Achieving the effective level to improve outcomes,
7.3 references 83
resulting from this trial, should be the goal to reach in future trials.
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8
F U T U R E L I N E S O F R E S E A R C H
The results from the research presented by this thesis, open different
lines of research:
In breast cancer screening, there is a non-negligible overdiagnosis
in Catalonia according to our results. Thus, breast cancer screening is
not free of adverse effects that should be well understood in order to
design risk-based screening programs for women to have the oppor-
tunity of an informed decision to take a screening mammography or
not.
Indeed, a line of research entitled Population participation in decisions
and strategies for breast cancer screening was iniciated with the following
objectives: 1) To assess the acceptability, effectiveness and feasibility
of a shared-decision making model for the early detection of breast
cancer program (EDBCP); 2) To explore the intention of women to
participate in a risk-based EDBCP and to evaluate its feasibility in a
shared decision making context. Shared decision-making is a model
of patient-centered care that enables and encourages people to play
a role in the management of their own health. It operates under the
premise that, armed with good information, consumers can and will
participate in the medical decision-making process by asking relevant
questions and expressing personal values and opinions about their
conditions and treatment options.The first aim implies to provide
complete and up-to-date information to women invited to participate
in a screening program. The second aim tries to individually balance
the benefits and harms of the early detection of breast cancer.
For cancer patients in general, there is an obvious lack of random-
ized controlled trials assessing the effect of supplementation with
cholecalciferol or ergocalciferol (both of them inactive vitamin D me-
tabolites), in spite of the high prevalence of vitamin D deficiency in
cancer patients and the recognized benefits of a normal vitamin D
status in the general population. Our preliminary results, from the
cross-sectional study on advanced cancer patients in palliative care,
show a significant association in the direction of a lower experience
of fatigue and higher physical performance and wellbeing for the
group of patients in the highest tertile of vitamin D serum levels. Our
design of the randomized controlled trial VIDAFACT is an attempt to
demonstrate the possible benefits in quality of life, fatigue and phys-
ical performance, and wellbeing of supplementing advanced cancer
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patients with cholecalciferol. If the future results of this trial confirm
our hypothesis, it will open multiple lines of basic and clinical re-
search. The first one will be to establish if there is a dosis-response
effect of the supplementation with vitamin D and the serum vitamin
D levels associated with patient-reported significant improvement in
quality of life and fatigue. No less important will be to determine
the best personalized daily dosage of cholecalciferol according to
the metabolism capacity of each patient. Thus, identifying patient’s
characteristics that significantly impact on vitamin D metabolism and
transformation into calcidiol and its hormonally active metabolite cal-
citriol is needed.
Part IV
C O N C L U S I O N S

9
M A I N F I N D I N G S
9.1 breast cancer incidence and overdiagnosis
1. There has been an increase in the incidence of invasive breast
cancer in Catalan women, especially in cohorts born from 1940
to 1955.
2. The highest increase was observed between the ages of 50 to 65
in cohorts born from 1940 to 1955, where the final BC incidence
rates more than doubled the initial ones.
3. Dissemination of screening mammography was significantly as-
sociated with breast cancer incidence and overdiagnosis.
4. Our model-based estimates of overdiagnosis ranged from 0.4%
to 46.6%, for women born from 1935 to 1950, supporting the
existence of overdiagnosis of breast cancer screening by mam-
mography in Catalonia.
5. The limited malignant potential of some screening-detected BC
tumors may play an important role in overdiagnosis.
6. Given the non-negligible estimated overdiagnosis in Catalonia,
women should be clearly informed about the benefits and harms
of participating in breast cancer screening.
9.2 vitamin d and cancer
7. There is no published phase III randomized controlled trial as-
sessing vitamin D (D2 or D3) efficacy on patient-reported fa-
tigue, pain or quality of life in advanced cancer patients.
8. Twenty one studies have been included in a systematic review
on outcomes in cancer patients after vitamin D2 or D3 supple-
mentation. These studies are highly heterogeneous in vitamin
89
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D daily dose and in treatment duration. Nevertheless, it could
be extrapolated that to correct serum vitamin D concentrations,
vitamin D3 must be at least 2,000 IU/day, a dose higher than
the recommended dietary intake for adults.
9. When assessing the associations between 25(OH)D levels and
some aspects measuring the quality of life, as reported herein
in cancer patients undergoing palliative care, patients reach-
ing higher circulating concentrations experienced significantly
lower fatigue and better physical performance, physical and
functional well-being, in comparison to patients with lower se-
rum vitamin D levels.
10. Fatigue is the symptom with the highest perceived impact in
advanced cancer patients in palliative care, closely followed by
pain.
11. The associations between 25(OH)D and fatigue, physical per-
formance, and physical and functional well-being, in advanced
cancer patients in palliative care, support the new trial supple-
menting patients with vitamin D to reduce fatigue and improve
their physical and functional status.
12. A randomised triple-blind phase II/III placebo-controlled mul-
ticentre trial has been designed: VIDAFACT, a safe, inexpensive
vitamin D supplementation in patients in palliative care, to con-
clusively address whether the quality of life for these patients
could benefit from the pro-survival properties of a normal vita-
min D status.
